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Sequencing studies performed in recent decades have revealed that the cells of 
most eukaryotic organisms express a diverse repertoire of small RNAs.  Genetic 
and biochemical investigation of these molecules has demonstrated that many 
small RNAs, most notably the microRNA subclass, possess the capacity to 
influence the expression of other genes, adding substantial complexity to our 
understanding of genetic regulatory networks.  In the years since their initial 
discovery, microRNAs have been implicated in nearly every aspect of metazoan 
biology, including medically relevant processes such as the development of 
mammalian immune cells and the oncogenic transformation of such cells into 
leukemias and lymphomas.  Even in these well-studied systems, however, the 
function of only a small fraction of microRNAs is understood, and novel RNAs 
may yet remain undiscovered.  Thus, in order to better define the microRNA 
landscape of both normal mature B cells and their oncogenic counterparts, we 
undertook sequencing of their small RNA transcriptomes.  In addition to 
microRNAs, these studies unexpectedly identified a class of RNA fragments 
whose sequences matched to transfer RNA, but whose size distribution 
    
resembled that of microRNAs.  Deep sequencing of small RNAs from a panel of 
normal mature B cells and B cell lymphomas reveals that these cell types 
express thousands of unique transfer RNA-derived fragments, with highly distinct 
expression profiles in each biological subtype.  We hypothesized that these 
fragments might be derived from direct processing of tRNA but nonetheless 
function as microRNA, and sought to experimentally characterize one 
representative sequence of this class, cloned from human mature B cells and 
designated CU1276.  The resulting data demonstrate that CU1276 does indeed 
possesses the functional characteristics of a microRNA, including a DICER1-
dependent biogenesis, physical association with Argonaute proteins, and the 
ability to repress mRNA transcripts in a sequence-specific manner.  Specifically, 
CU1276 represses endogenous expression of RPA1, a gene with critical 
functions in many aspects of DNA dynamics, including replication and repair.  
CU1276 is abundantly expressed in normal mature B cells but strongly 
downregulated in B cell-derived lymphomas, while its target, RPA1, is 
overexpressed in lymphomas.  Furthermore, enforced expression of CU1276 in a 
lymphoma cell line results in an RPA1-dependent impairment of both proliferation 
and DNA damage repair.  These results suggest that relief from CU1276-
mediated repression of RPA1 may confer a selective advantage to lymphoma 
cells, and they shed light on a possible regulatory role for transfer RNA-derived 
microRNA in the in the maturation of normal B cells.  Taken together with 
published data, these results suggest that in a broad spectrum of organisms and 
    
tissues, transfer RNAs act as a previously unrecognized substrate for the 
biogenesis of microRNA, with substantial implications for the future study of small 
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Chapter 1:  B cells, B cell lymphomas, and 
microRNA signaling  
 
PREFACE 
In the fall of 1993, unbeknownst to all but a few scientists, a quiet revolution was 
underway in molecular biology.  Buried in the December issue of the scientific 
journal Cell were dual reports, from the laboratories of Gary Ruvkun and Victor 
Ambros, of an unusual genetic interaction between a small, untranslated RNA 
called lin-4, and a the protein coding gene lin-14 (Lee et al., 1993; Wightman et 
al., 1993).  These papers suggested that the mechanism by which lin-4 regulated 
expression of lin-14 was quite different than any that had been previously 
described in animal systems.  As with many scientific discoveries, the 
publications raised as many questions as they answered, and their general 
importance was not immediately clear.  However, with the benefit of nearly 
twenty years of hindsight, it is now easy to recognize that these papers mark the 
beginning of a “paradigm shift” in our understanding of genetic regulatory 
networks. 
 This much-abused phrase, first codified by Thomas Kuhn in his classic work 
of scientific philosophy, The Structure of Scientific Revolutions (Kuhn, 1962), 
refers not simply to a discovery, or to a falsification of a theory, but to a 
fundamental, discipline-wide change of perspective that requires re-examination 
of all previous work.  Such shifts occur only rarely in biology, but Ruvkun, 
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Ambros, and colleagues managed the feat by discovering a new class of 
regulatory molecule that, for all practical purposes, had been invisible to 
researchers for the entire previous span of scientific history.  These regulatory 
molecules would later come to be known as microRNAs (Ruvkun, 2001), and far 
from being an idiosyncrasy of Caenorhabtidis elegans, the model organism in 
which they were first discovered, microRNAs would be found to play important 
roles in almost every area of metazoan biology. 
 From the maintenance of pluirpotency in stem cells (Judson et al., 2009) to 
the patterning of limbs during development (Hornstein et al., 2005) to the 
development of antibody-producing immune cells (Chen et al., 2004; Xu et al., 
2012) and the transformation of those same cells into leukemias and lymphomas 
(He et al., 2005; Klein et al., 2010), by now it is clear that microRNAs are 
important pieces of the genetic regulatory machinery that transmutes the static 
information of DNA into dynamic cells, tissues, and organisms.  However, after 
two decades of study, the microRNA field is still in awkward adolescence.  
MicroRNAs continue to surprise us by bypassing key components of their normal 
biogenesis pathway (Ender et al., 2008; Ladewig et al., 2012), by disregarding 
the canonical rules of target binding (Brennecke et al., 2005; Tay et al., 2008), or 
by imposing unexpected consequences upon the targets to which they bind 
(Orom et al., 2008; Vasudevan et al., 2007). 
 The work presented here highlights yet another surprising aspect of 
microRNA biology by demonstrating an unexpected mechanism for the 
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biogenesis of microRNAs:  cleavage of mature transfer RNA transcripts.  We find 
that human mature B cells, the critical mediators of the adaptive immune 
response and cell of origin for a broad spectrum of leukemias and lymphomas, 
express a diverse collection of small RNA fragments derived from tRNA (Basso 
et al., 2009), and that at least one such sequence can act as a fully functional 
microRNA (Chapter 3).  Taken together with other recently published reports 
(reviewed in Sobala and Hutvagner, 2011), these results suggest that in a variety 
of organisms and cell types, transfer RNAs can be readily co-opted as grist for 
the mill of microRNA signaling, producing a large pool of regulatory small RNAs 
that have thus far gone largely unstudied (Chapter 4).  The full biological role of 
these molecules remains to be determined, but further investigations are certain 
to turn up additional surprises. 
 
THE B CELL SYSTEM 
In order to survive and reproduce, all organisms must resist attack from a 
staggering legion of pathogens in their environment.  The majority of multicellular 
organisms defend themselves by deploying specialized immune cells to 
neutralize or destroy threats.  Vertebrates, in particular, have evolved an elegant 
and multi-faceted arsenal comprised of dozens of immune cell types, each 
fulfilling critical and interdependent roles in preventing infection.  Within this 
complexity, the immune response in vertebrates can broadly be subdivided into 
two branches:  innate immunity, and adaptive immunity (Delves and Roitt, 2000; 
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Medzhitov and Janeway, 2000). 
 Innate immunity is by far the more ancient of the two systems; it is found in 
some form in all metazoans, and shares genetic modules with an analogous 
immune system in plants (Medzhitov and Janeway, 2000).  Although precise 
details differ across such widely divergent biological classes, the core function of 
the innate immune system is to recognize and sequester or destroy pathogens 
using inherited, germline-encoded proteins.  A key set of tools in this process are 
invariant receptors, expressed by a subset of cells of the innate immune system, 
that bind to molecules such as lipopolysaccharides, mannans, 
phosphorylcholine, and lectins, groups of molecules that are expressed on the 
surface of pathogens such as bacteria, viruses, or fungi, but not by host cells 
(Takeuchi and Akira, 2010).  Binding of these foreign surface molecules marks 
the pathogens for phagocytosis and destruction. 
 Once a pathogen has breached physical barriers to entry into a host 
organism, innate immunity is the first line of defense against further damage.  
Most infections are successfully prevented or stopped at an early stage by the 
innate immune response, and indeed, this system is the sole active defense 
against infection in the majority of organisms on earth (Cooper and Alder, 2006).  
However, the ultimate effectiveness of the innate immune system is hampered by 
structural limitations.  Pattern recognition receptors and other components of 
pathogen identification are germline-encoded; therefore, the attack strategies of 
innate immunity are restricted to general targets, not specific to any single 
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pathogenic agent (Janeway and Medzhitov, 2002).  Furthermore, in the 
evolutionary arms race of host-pathogen interactions, the speed at which the 
genetic components of innate immunity can adapt and evolve is quite slow; over 
a given window of time, pathogens such as viruses and bacteria, with their short 
generation times and high rates of mutation, may have the potential to 
overwhelm or evade host immune responses. 
 Uniquely among all clades, jawed vertebrates have successfully evolved a 
solution to this challenge:  the adaptive immune system (Cooper and Alder, 
2006).  Rather than relying only on invariant molecules to recognize and bind 
pathogens, the adaptive immune system allows the host to continuously sample 
foreign agents, and to develop highly specific proteins to bind them.  Like the 
innate immune system, the adaptive immune system is subject to the basic 
constraints of any biological process:  it must operate using a finite number of 
genes.  However, through an elegant system of highly regulated somatic 
rearrangements and mutations of their DNA, the cells of the adaptive immune 
system are able to shuffle and edit these finite building blocks into nearly limitless 
variations, and following a rapid process of selection and refinement, can 
produce molecules capable of responding to nearly any pathogenic challenge 
with a high degree of potency and specificity (Delves and Roitt, 2000). 
 Classically, the adaptive immune response can be subcategorized into two 
primary mechanisms:  cell-mediated immunity, which is facilitated by contact- or 
cytokine-based activation of phagocytes, natural killer cells, or cytotoxic T cells; 
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and humoral immunity, which is facilitated by soluble or cell-bound antibodies.  
Both processes depend on genetic rearrangement and mutation in order to 
mount a potent and specific response. 
 The central mediators of the humoral adaptive immune response are 
antibodies, also known as immunoglobulins.  Antibodies are proteins products of 
the immune system, capable of binding foreign molecules, known as antigens, 
and marking them for destruction by immune cells such as phagocytes (Delves 
and Roitt, 2000).  They can exist in both soluble and cell membrane-bound 
forms, and are produced by cells of the B lymphocyte lineage (Delves and Roitt, 
2000).  B lymphocytes, more simply known as B cells, are named for the Bursa 
of Fabricius, a hematopoietic organ that is the site of their development in avian 
systems (McCormack et al., 1991).  In most mammals, however, these cells 
initially develop in the fetal liver, and then in the adult bone marrow (Hardy and 
Hayakawa, 2001). 
 Through several rounds of asymmetric division, multipotent hematopoietic 
stem cells (HSCs) in the bone marrow give rise to lymphocyte progenitors, which 
give rise to immature B cells.  Starting from this point in their development, every 
stage of B cell development is defined by alterations in the genetic loci encoding 
their immunoglobulin genes (Klein and Dalla-Favera, 2008; Schatz and Swanson, 
2011).  Each successive alteration event increases the diversity of the possible 
immunoglobulin pool, providing additional opportunity to generate antibody 
molecules with high-affinity binding to foreign antigens. 
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 In physical structure, an antibody molecule is symmetrically composed of 
two sets of paired segments, each containing one immunoglobulin heavy chain 
peptide and one immunoglobulin light chain peptide.  Heavy and light chains are 
built of distinct segments, known as the Variable (V), Diversity (D), Joining (J), 
and Constant (C) regions (Delves and Roitt, 2000).  Both heavy and light chain 
loci encode V, J, and C regions, while D regions are particular to the heavy chain 
(Matsuda et al., 1998).  The genetic loci of the immunoglobulin chains are 
complex, and encode a tandem array of multiple versions of each V, D, and J 
segment.  Each gene segment is flanked by specific gene elements of either 12 
or 23 base pairs, known as recombination signal sequences (RSS) (Schatz and 
Swanson, 2011).  Each V, D, and J segment in the genome is of distinct DNA 
sequence, and therefore contributes a unique set of binding properties to a 
resulting antibody molecule.  Ultimately, only one version of each segment type 
per cell will contribute to expression of an immunoglobulin chain (Delves and 
Roitt, 2000); the choice of which genetic building block to use is determined 
during the first genetic editing process of B cell maturation, known as VDJ 
recombination (Delves and Roitt, 2000). 
 Upon differentiation of lymphoid progenitors into the most immature type of 
B cell, known as the pre-pro-B cell, expression of Recombination Activating Gene 
1 and Recombination Activating Gene 2 (RAG1 and RAG2, respectively) initiates 
the process of VDJ recombination (Schatz and Swanson, 2011).  These enzymes 
induce double strand breaks within the RSS flanking the V, D, and J segments, 
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and act to recruit the assembly of non-homologous end joining (NHEJ) 
complexes (Schatz and Swanson, 2011).  Proper repair of the RAG-induced 
breaks by NHEJ components results in contiguous linking of immunoglobulin 
gene segments, with an accompanying excision of intervening sequences.  This 
linkage produces a locus capable of expressing an immunoglobulin heavy or light 
chain peptide comprised of a nearly random combination of a single variant each 
of the critical V, D, and J segments.  In order for a B cell to progress along its 
developmental path, both heavy and light chain immunoglobulin loci must 
undergo this process of genetic rearrangement; once these rearrangements are 
completed, the cell can express a complete immunoglobulin molecule.  This 
process occurs initially on only a single immunoglobulin allele; if the cell then fails 
to produce a functional immunoglobulin molecule, a process known as allelic 
exclusion will transcriptionally inactivate the rearranged immunoglobulin allele, 
and will proceed to recombine the second allele.  Thus allelic exclusion ensures 
that each B cell produces one and only one variety of rearranged immunoglobulin 
(Bergman and Cedar, 2004). 
 Upon cell-surface expression of a properly rearranged immunoglobulin, also 
known in its membrane-bound form as a B cell receptor (BCR), the cell is 
considered to have left the pro-B stage and is classified as an immature B cell 
(Delves and Roitt, 2000).  Based on the particular combination of immunoglobulin 
segments linked during VDJ recombination, each immature B cell will express a 
BCR with different binding specificity.  Some of these combinations, however, are 
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inherently reactive against antigens produced normally by the host.  Thus, in 
order to prevent the mounting of a humoral immune response against the host 
itself, immature B cells are subjected to a process of selection that eliminates 
clonal lineages encoding for BCR molecules with the ability to bind host antigens.  
Strong binding to “self” antigen at this stage induces apoptosis in the cell, while 
weaker binding results either in entry to an inactive state known as anergy, or to 
another round of rearrangement of the remaining immunoglobulin VDJ segments 
by RAG proteins; if this second round of rearrangement fails to eliminate the self-
reactivity of the resulting BCR molecule, the cell will undergo apoptosis (Hardy 
and Hayakawa, 2001). 
 B cells that successfully produce a complete immunoglobulin molecule and 
that pass the host antigen-binding test are considered to be mature B cells 
(Delves and Roitt, 2000).  They subsequently migrate from the bone marrow to 
the secondary lymphoid tissues, including the spleen, lymph nodes, tonsils, and 
intestinal Peyerʼs Patches (Delves and Roitt, 2000).  Once homed to these 
locations, naïve B cells, so-called because they have not yet encountered any 
antigen specifically bound by their encoded immunoglobulin molecule, have the 
opportunity to receive further developmental signals.  Such signals include 
binding to antigen, or co-stimulation from other immune cells.  For a fraction of 
cells, the proper combination of signals, indicative of an already-potent antigen 
binding capability, can induce clonal proliferation of the B cell and direct 
differentiation into terminal B cell lineages (Klein and Dalla-Favera, 2008).  In the 
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majority of B cells, however, the binding of antigen and co-stimulatory signals 
from helper T cells induces the further genetic diversification of the 
immunoglobulin loci; these additional DNA editing processes occur within a 
structure known as the germinal center (GC) (Klein and Dalla-Favera, 2008). 
 Upon antigen binding and stimulation by helper T cells, the formerly naïve B 
cells begin to proliferate, and over the course of several days this mass of 
proliferating cells organizes to form a histologically identifiable GC follicle.  The 
physical structure of the GC can roughly be divided into three parts:  the mantle 
zone, which rings the periphery of the GC follicle and is comprised of naïve B 
cells not yet stimulated by antigen; the dark zone, densely-packed with B cells 
known as centroblasts; and the light zone, comprised primarily of smaller B cells 
known as centrocytes, as well as antigen-presenting dendritic cells (Klein and 
Dalla-Favera, 2008).  Within the specialized physical environment of the dark and 
light zones, GC B cells execute a genetic program unlike any other in eukaryotic 
biology (Victora and Nussenzweig, 2012). 
 The single most important genetic regulator expressed in the GC is the 
transcription factor BCL6 (Basso and Dalla-Favera, 2012).  This gene was first 
identified based on its involvement in translocations in diffuse large B cell 
lymphoma (Baron et al., 1993; Kerckaert et al., 1993; Ye et al., 1993a; Ye et al., 
1993b), and genetic experiments subsequently demonstrated that misregulated 
expression of BCL6 directly contributes to the development of lymphoma 
(Cattoretti et al., 2005).  Like many cancer-relevant genes, however, BCL6 is also 
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an important regulator of normal cellular function; specifically, its timely 
expression is strictly required for normal GC development (Dent, 1997; Fukuda et 
al., 1997; Ye et al., 1997).  Extensive study of BCL6 has revealed that its 
expression in B cells is virtually synonymous with a GC identity (Klein and Dalla-
Favera, 2008). 
 The physiologic function of the GC environment is to continuously generate 
a wide diversity of modified immunoglobulin genes, while selecting B cell clones 
that encode high-affinity antibodies and discarding those that do not.  To achieve 
this, BCL6 facilitates a genetic program that acts to promote proliferation, 
tolerance of DNA damage, and insulation from outside signals in GC B cells 
(Basso et al., 2010).  The B cells of the GC proliferate at an extraordinarily rapid 
pace, with a doubling time of less than 12 hours (Allen et al., 2007).  In order to 
maintain their replicative potential and avoid senescence across many cell 
divisions, GC B cells prevent shortening of their telomeres through expression of 
the enzyme telomerase, and repress expression of the senescence factor 
CDKN1A (Klein et al., 2003).  However, unlike most proliferating cells, GC B cells 
also lack the expression of several key anti-apoptotic factors and are therefore 
primed for programmed cell death (Klein et al., 2003; Martinez-Valdez et al., 
1996).  Perhaps most strikingly, and in stark contrast to other proliferating cell 
populations in the body, GC cells also strongly suppress the sensing of, and 
molecular response to DNA damage (Hu et al., 1997; Phan and Dalla-Favera, 
2004), a suppression that is necessary for the proper generation of 
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immunoglobulin diversity through the processes of DNA modification that occur in 
the GC. 
 The net result of these contradictory genetic programs is to allow explosive 
growth of B cell clones as they undergo substantial DNA mutation and 
rearrangement of immunoglobulin loci.  The progeny of these cells are set on a 
default path of apoptosis, unless rescued by positive signaling from high-affinity 
interaction between BCR and antigen (Klein and Dalla-Favera, 2008).  Such high 
affinity binding can be achieved through a process known as somatic 
hypermutation (SHM) (Victora and Nussenzweig, 2012). 
 After VDJ recombination, SHM is the second major DNA editing process 
during B cell development, and is a critical step in the generation of diversity 
within immunoglobulin genes.  It primarily, although not exclusively, occurs in the 
GC (Teng and Papavasiliou, 2007).  SHM is initiated by in dark zone centroblast 
B cells by the expression of the enzyme Activation Induced Deaminase (AICDA).  
Once in the nucleus, this enzyme promotes mutations, primarily single nucleotide 
exchanges, in the V region of immunoglobulin genes at a rate of approximately 
10-3 mutations per base pair per cell division (Rajewsky et al., 1987).  AICDA 
facilitates this process through the deamination of cytidines in the V region of 
DNA; subsequent correction of these events by one of several different error-
prone DNA repair factors introduces heritable somatic mutations (Teng and 
Papavasiliou, 2007).  AICDA function is dependent on phosphorylation by protein 
kinase A (PKA) (Basu et al., 2005; Pasqualucci et al., 2006), and on the large 
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70kD subunit of the replication protein A complex, RPA1 (Chaudhuri et al., 2004).  
However, the precise mechanism by which this enzyme is specifically targeted to 
immunoglobulin V regions, but only comparatively rarely to other genes, is still 
unknown. 
 The resulting changes in immunoglobulin V regions generate sequence 
diversity, but with the possibility of either increasing or decreasing the affinity of 
the immunoglobulin molecule for antigen.  A process of selection known as 
affinity maturation directs the clonal evolution of GC B cells toward production of 
potent and specific antibodies.  After undergoing SHM in the dark zone, B cells 
migrate to the light zone, where follicular dendritic cells present antigen to 
surrounding B cells in limiting quantities (Victora and Nussenzweig, 2012; Victora 
et al., 2010).  Binding of antigen to the BCR induces a signaling cascade that 
promotes survival, while lack of binding results in death.  GC B cells with 
moderate levels of antigen affinity survive and are re-circulated to the dark zone, 
where they undergo additional SHM (Klein and Dalla-Favera, 2008).  Those with 
high antigen affinity are induced to undergo a third DNA editing process called 
class switch recombination (CSR). 
 Like the V, D, and J regions, the constant (C) region of immunoglobulin loci 
is encoded by multiple versions of distinct sequence.  The different versions of 
the C region do not affect specificity for antigen, but instead influence the form of 
the expressed antibody molecule, and consequently the repertoire of effector 
molecules with which it can interact (Harriman et al., 1993).  There are five 
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different immunoglobulin classes, each named for its corresponding constant 
region:  IgM, IgD, IgA, IgE, and IgG.  Prior to arrival in the GC, B cells can 
express only two of the six classes of immunoglobulin:  IgM, which is the default 
antibody class due to the positioning of its corresponding C region first among 
the constant region segments, and IgD, which can be expressed via alternative 
splicing of immunoglobulin mRNA (Ohta and Flajnik, 2006).  The other classes of 
immunoglobulin can only be expressed following a successful CSR event. 
 As in SHM, the enzyme AICDA initiates the process of CSR (Muramatsu et 
al., 2000); also like SHM, CSR occurs primarily, but not exclusively, within the GC 
environment (Klein and Dalla-Favera, 2008).  AICDA-mediated deamination of 
both donor and acceptor switch regions, followed by additional enzymatic 
processing, induces double-strand breaks in the DNA strands of C regions.  
Repair of these breaks by NHEJ excises intervening sequences, joining together 
the unaltered VDJ regions of an immunoglobulin chain with a new C region.  
Although external signals, particularly from light-zone T cells, clearly influence 
this process, the mechanism of AICDA targeting to precise C regions, and the 
consequent choice of antibody isotype, is not well understood (Klein and Dalla-
Favera, 2008).  CSR can take place differently in the various cells of a B cell 
clone without affecting the previously rearranged and mutated VDJ regions of the 
immunoglobulin chains, thus producing all possible classes of a given antibody, 




B CELL LEUKEMIA AND LYMPHOMA 
Together, the complementary processes of VDJ recombination, SHM, and CSR 
enable B cells to produce a nearly limitless variety of antibodies; coupled with the 
selective processes of the GC, the adaptive immune system is able to parlay a 
small handful of genes into an extraordinarily flexible pathogen-fighting toolkit.  
However, in the process of fighting off external threats, the B cells of the adaptive 
immune system can occasionally give rise to an internal one:  lymphoma. 
 VDJ recombination, SHM, and CSR actively introduce mutations and 
double-strand breaks to DNA; such genetic alterations lie at the roots of most 
oncogenic transformations, and thus they pose a potential risk to the B cell 
lineage.  Genetic analysis of B cell lymphomas reveals that the majority have 
undergone SHM, demonstrating that these tumors are in fact derived from GC or 
post-GC cells (Klein and Dalla-Favera, 2008).  Indeed, the specialized 
environment of the GC is a dangerous place, coupling active DNA alteration with 
rapid proliferation and a suppression of the DNA damage response.  Under these 
conditions, the machinery of SHM and CSR can sometimes go awry, inducing 
mutations or chromosomal aberrations that can affect the regulation or 
functionality of critical tumor suppressors and oncogenes.  The relationship 
between the mutagenic processes of the GC and lymphoma development is 
amply demonstrated by studies in which genetic deletion of Aicda in a cohort of 
lymphoma-prone mice blocked the development of GC-derived tumors 
(Pasqualucci et al., 2008).  The enormous benefits of the adaptive immune 
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system are therefore slightly tempered by its potential to facilitate 
lymphomagenesis. 
 GC derived cancers include a number of subtypes, each characterized by a 
distinct molecular pathogenesis.  Examples include Burkitt Lymphoma, which is 
largely defined by the presence of chromosomal translocations that deregulate 
the MYC oncogene by placing it under transcriptional control of highly expressed 
immunoglobulin loci (Kuppers and Dalla-Favera, 2001); follicular lymphoma, 
which carries translocations that deregulate the expression of the anti-apoptotic 
protein BCL2 and thus allows these cells to resist apoptotic pressures of the GC 
(Dalla-Favera et al., 1982; Kuppers and Dalla-Favera, 2001); diffuse large B Cell 
lymphoma, in which a heterogeneous mixture of genetic aberrations can 
deregulate a number of important signaling genes, including BCL6, BCL2 , MYC , 
CREBBP , and members of the NF-κB pathway (Pasqualucci et al., 2011; 
Schneider et al., 2011); and chronic lymphocytic leukemia, a mostly indolent 
cancer which arises from post-GC memory B cells and is the result of disrupted 
apoptotic and growth signaling (Klein and Dalla-Favera, 2010).  Each of these 
tumor types can harbor multiple genetic gains, losses, or somatic, non-
synonymous mutations in one or more regulators responsible for the control of 
growth signaling, chromatin maintenance, cellular differentiation, or DNA damage 
signaling.  The common factor linking genetic alterations often observed in 
mature B cell malignancies is the disruption of some aspect of the GC genetic 
program (Klein and Dalla-Favera, 2008; Kuppers, 2005). 
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 As with many cancers, current treatment regimes for B cell lymphomas are 
based on chemotherapeutic drugs with general toxicity for proliferating cells 
(Schneider et al., 2011).  Although B cell lymphomas typically have better 
survival outcomes than many solid tumors, therapies designed to target or exploit 
specific genetic drivers of oncogenic growth are the best hope to achieve 
significant future improvements in survival for the patients of these diseases 
(Schneider et al., 2011).  Success in this endeavor will be dependent on 
knowledge of the full spectrum of their molecular pathogenesis, a process that 
will combine cataloguing of genetic alterations identified in tumors with thorough 
study of the normal regulation of B cell development. 
 
THE BIOGENESIS AND SIGNALING DYNAMICS OF MICRORNAS 
Twenty years ago, work in C. elegans revealed that the lin-4 gene represented a 
unique archetype for a genetic regulator: unlike well-studied protein coding 
genes, lin-4 was an untranslated RNA able to post-transcriptionally repress 
expression of a protein coding gene, lin-14, through partially complementary 
binding sites within the 3ʼ untranslated region of the lin-14 mRNA transcript (Lee 
et al., 1993; Wightman et al., 1993).  In the years immediately following these 
reports, the unusual characteristics of the lin-4 gene received little attention, 
given the fact that no similar small RNA seemed to be encoded in the genomes 
of other model organisms.  However, seven years later, the report of a second 
miRNA that was broadly conserved across many species (Reinhart et al., 2000) 
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mobilized scientists working outside of the C. elegans system to look for further 
examples of these curious new small RNA molecules, which would eventually be 
known as microRNAs (miRNAs) (Ruvkun, 2001).  The subsequent decade has 
brought a dramatic increase in our understanding of miRNA biogenesis and 
function.  It is now clear that in organisms whose genomes encode for miRNAs, 
these small RNAs play an important regulatory role in the majority of biological 
processes.  In mammalian systems, their role in the normal development of 
immune cells, and in the oncogenic transformation of these cells into leukemias 
and lymphomas, has been the subject of particularly thorough investigation (Di 
Lisio et al., 2012; Fabbri et al., 2008; Fernando et al., 2012). 
 Typically, miRNAs are expressed as part of long primary transcripts, either 
alone or in a cluster of miRNAs, located within exonic or intronic regions, in either 
non-coding or protein-coding mRNAs (He and Hannon, 2004).  These miRNA-
encoding transcripts are typically capped, polyadenylated RNA polymerase II-
generated RNAs (Lee et al., 2004).  After transcription, they will fold into a 
characteristic hairpin secondary structure that can be recognized and bound by 
the DGCR8 protein (Yeom et al., 2006), and subsequently cleaved by the RNase 
III enzyme DROSHA (Lee et al., 2003).  Once separated from the primary 
transcript, the resulting long hairpin, also known as the precursor microRNA (pre-
miRNA) is exported from the nucleus into the cytoplasm by the XPO5 complex 
(Yi et al., 2003).  In the cytoplasm, pre-miRNA are bound and cleaved by a 
second RNase III enzyme, DICER1, to liberate a short, double-stranded RNA 
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duplex, ~18-23 nucleotides in length (Bernstein et al., 2001).  From this duplex, 
one of the two strands will be loaded into an Argonaute family protein.  The 
functional unit made up of this core Argonaute protein, its associated protein 
factors, and the bound miRNA are together known as a miRNA induced silencing 
complex (miRISC) (Hammond et al., 2001).  In humans, there are four Argonaute 
proteins associated with miRNA silencing:  Ago1 (EIF2C1), Ago2 (EIF2C2), Ago3 
(EIF2C3), and Ago4 (EIF2C4).  Ago2 is unique among these proteins in that it 
possesses RNA endonucleolytic activity (Liu et al., 2004; Meister et al., 2004).  
Although Ago1 and Ago2 are most commonly associated with miRNA function, in 
fact, all four Argonaute proteins are able to bind miRNAs and facilitate miRNA-
mediated gene repression (Su et al., 2009). 
 The choice of which miRNA strand to load into the Argonaute protein is 
dictated in part by the relative binding energy of each component of the RNA 
duplex, with a lower 5ʼ thermodynamic stability contributing to miRISC 
incorporation (Schwarz et al., 2003).  For some miRNA, only one of the two 
strands will be consistently loaded into miRISC, while the other is rapidly 
degraded; in these cases, the loaded and unloaded strands are referred to as the 
miR and the miR*, respectively.  However, for many other miRNAs, the relative 
steady-state abundances of the two strands are similar or equal, meaning that a 
single pre-miRNA gives rise to two distinct mature miRNA.  Furthermore, the 
miR* sequence of abundant pre-miRNAs may be orders of magnitude more 
common than the miR sequence of low abundance pre-miRNAs.  Therefore, the 
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miR/miR* nomenclature is currently being phased out in favor of an abundance-
neutral system in which the 5ʼ-most miRNA product is denoted as the miR-5p, 
while the 3ʼ-most miRNA product is denoted as the miR-3p. 
 Once incorporated into miRISC, the mature miRNA acts as a specificity 
module to guide the repressive activity of the Argonaute proteins, directing them 
to bind at complementary sites in the 3ʼ UTR of mRNA transcripts (Ladewig et al., 
2012).  In animals, these sites are usually of imperfect complementarity, with a 
canonical interaction requiring only perfect Watson-Crick base pairing of miRNA 
nucleotides 2-9, known as the “seed” sequence (Lewis et al., 2003).  The 
consequence of miRNA binding is typically repression of the target through one 
of several mechanisms.  Perfect or near-perfect pairing can induce 
endonucleolytic cleavage of the mRNA; in humans, Ago2 possesses the “slicer” 
activity required for mRNA cleavage in this way, while Ago1, Ago3, and Ago4 do 
not (Liu et al., 2004; Meister et al., 2004).  More commonly, miRISC binding 
results in repression at the level of translation or in destabilization and 
exonucleolytic degradation of the target mRNA (He and Hannon, 2004).  Recent 
work has suggested that in mammalian cells, most or all of the repressive effect 
of a miRNA can be attributed to mRNA-level changes alone (Guo et al., 2010), 
but these results have yet to be fully reconciled with a number of previously 
documented examples of translational repression with only small effects on 
mRNA levels (Baek et al., 2008; Selbach et al., 2008; Zeng, 2003). 
 Owing to their distinct biogenesis and mechanism of action, the dynamics of 
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miRNA-mediated gene regulation differ from those of other genetic regulators.  
MiRNAs are immediately active upon transcription and processing, without the 
need for ribosomal translation; furthermore, they act directly on mRNA 
transcripts, not on DNA or protein.  The kinetics of miRNA-mediated repression in 
blocking gene activity are therefore considerably different, and in many cases, 
faster, than those of either a transcription factor or a post-translational repressor 
(Baccarini et al., 2011; Khanin and Vinciotti, 2008).  And although miRNA 
expression can have biologically important regulatory consequences, the overall 
magnitude of miRNA-mediated regulation is often more modest than regulation 
which might be observed upon a comparable transcriptional or post-translational 
interaction.  Additionally, unlike transcriptional or post-translational regulators, all 
miRNAs must compete both for space within the Argonaute-containing 
complexes that facilitate their repression, and they must also vie for access to a 
shifting array of mRNA targets available in the cell.  Thus, changes in the 
expression level of a target mRNA, even absent any changes in the expression 
of miRNAs themselves, can sometimes have dramatic effects on other genes 
that are targeted by a common set of miRNAs (Poliseno et al., 2010; Sumazin et 
al., 2011).  Taken together, the fundamental differences between miRNAs and 
other regulators may point to specific biological roles for which miRNAs may be 
particularly well-suited, such as rapid, fine-tuning of gene levels. 
 
NON-CANONICAL MICRORNA BIOGENESIS AND FUNCTION 
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In the relatively short time since their discovery, many general principles of 
miRNA biogenesis and function have been elucidated.  The majority of miRNA 
are generated and act according to standard mechanisms, as described in detail 
above:  they are produced from RNA polymerase II-generated transcripts, 
recognized by DGCR8, processed by DROSHA, transported out of the nucleus 
by XPO5, cleaved by DICER1, and concordantly loaded into miRISC; ultimately 
they bind to perfect seed sequence-matching sites in the 3ʼ UTRs of targets, with 
the consequence of RNA transcript destabilization or translational inhibition (He 
and Hannon, 2004).  However, there are few hard and fast rules when it comes 
to miRNAs, and exceptions or modifications to nearly all of these canonical steps 
have been described. 
 Approximately half of mammalian miRNAs are encoded within the introns of 
protein coding genes, and approximately half are encoded either within the 
intronic or exonic sequences of intergenic, long noncoding host RNA transcripts 
(Saini et al., 2007).  Both of these types of transcripts are produced by the RNA 
polymerase II holoenzyme (Pol II).  However, the RNA polymerase III complex 
(Pol III), normally responsible for the transcription of 5s Ribosomal RNA, transfer 
RNAs (tRNAs), spliceosomal RNAs, and other small RNA factors, can also 
transcribe miRNA-producing transcripts.  The first documented example of this 
phenomenon was observed for miRNAs encoded adjacent to Alu repeats in the 
human genome.  Like the Alu repeats themselves, which depend on Pol III for 
their transcription, these miRNAs are expressed in a Pol III-dependent manner 
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(Borchert et al., 2006).  Additionally, the genomes of several virus types, 
including adenoviruses and herpesviruses, also encode for miRNAs as 
components of Pol III generated transcripts (Bogerd et al., 2010; Diebel et al., 
2010; Kincaid et al., 2012). 
 Enzymatic processing by DROSHA is required to liberate the precursor 
hairpins for most miRNAs from their host transcripts, and DICER1 cleavage is in 
turn required to extract the mature miRNA sequence from its precursor, but 
several known miRNAs are able to evade this requirement.  For one such group 
of miRNAs, known as “miRtrons”, the pre-miRNA sequence itself composes the 
entirety of an mRNA transcript intron; thus, upon normal splicing, the miRNA 
precursor hairpin will be excised from the transcript independently of DROSHA 
function (Ladewig et al., 2012; Ruby et al., 2007).  MiRNA can also be derived 
from mature, functional small nucleolar RNA (snoRNA) in a DROSHA-
independent, but DICER1-dependent fashion (Ender et al., 2008), or from 
multicistronic viral tRNA primary transcripts, for which ELAC1 cleavage 
substitutes DROSHA processing (Bogerd et al., 2010).  Even the requirement for 
DICER1 cleavage can be evaded by at least one miRNA:  the biogenesis of miR-
451 is instead dependent on processing by the endonucleolytic activity of Ago2, 
into which it is directly loaded (Cheloufi et al., 2010; Cifuentes et al., 2010).  
Because the defects observed in mice with homozygous, constitutional knock-in 
of catalytically inactive Ago2 alleles can be wholly rescued by expression of miR-
451 (Cheloufi et al., 2010; Cifuentes et al., 2010), it is unclear whether this 
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particular mechanism of biogenesis is widespread, or limited specifically to miR-
451. 
 According to the prevailing dogma of miRNA targeting in animals, miRNAs 
bind to perfect seed-matched sites in the 3ʼ UTR of protein coding mRNA genes, 
leading to translational inhibition or mRNA destabilization.  Most computational 
miRNA target identification tools strictly rely on these assumptions (Lewis et al., 
2005; Lewis et al., 2003), but perhaps no other “rule” of miRNA biology is as 
frequently violated.  From the very earliest studies of miRNAs, there have been 
clear, validated examples of miRNA-target interactions that run contrary to these 
principles.  Indeed, the lin-4 repression of lin-14 translation that gave life to the 
miRNA field is at least partially mediated by sites with imperfect seed pairing and 
unusually large intervals of mismatch between regions of 5ʼ and 3ʼ base pairing 
(Lee et al., 1993).  Therefore, it is not entirely surprising that later studies have 
uncovered examples of miRNA-target interactions that can tolerate G-U base 
pairing, or that have mismatches to the seed sequence (Didiano and Hobert, 
2006), or that bind via sites in the protein coding sequence rather than in the 3ʼ 
UTR (Tay et al., 2008). 
 Even the ultimate consequences of miRNA binding are not entirely 
consistent.  The repressive effect of miRNAs has been shown in some cases to 
be cell cycle regulated, with repression occurring only during active proliferation, 
while a net increase of translation occurs upon cell cycle arrest (Vasudevan et 
al., 2007).  Certain miRNAs even bind to the 5ʼ UTR of ribosomal proteins, 
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directly increasing their translation through an unknown mechanism (Orom et al., 
2008). 
 Each case of non-canonical miRNA biogenesis or function may represent 
only a specialized exception to the standard model of miRNA signaling.  
Nonetheless, the sheer number of such mechanisms amply demonstrates that 
there is much still unknown about these important small RNA regulators.  Further 
investigation is likely to turn up additional examples of unexpected mechanisms 
involved in miRNA biogenesis, and new models for miRNA-mediated regulation. 
 
KNOWN ROLES OF MICRORNAS IN B CELL DEVELOPMENT AND 
LYMPHOMAGENESIS 
MiRNAs have been implicated in the regulation of many dozens of mammalian 
biological processes, but their role in the development of the immune system is 
especially well studied (Di Lisio et al., 2012; Fernando et al., 2012).  The 
essential role of miRNAs in the regulation of B cell development, in particular, is 
succinctly demonstrated by genetic deletion of Dicer1 in the B cell lineage of 
mice:  loss of Dicer1 function in this context arrests early B lymphocyte 
development at the pro- to pre-B cell transition, and thus reveals that miRNAs are 
critically important for even early stages of B cell development (Koralov et al., 
2008).  Beyond this wide-angle analysis, a number of individual miRNAs have 




 The first indication that miRNAs were important to the process of B cell 
development came only a few years after the discovery of miRNAs in mammals 
(Reinhart et al., 2000), when Bartel and colleagues reported that ectopic 
expression of the B cell-specific miR-181a in mouse multipotent HSCs increased 
the fraction of daughter cells that ultimately committed to the B cell lineage (Chen 
et al., 2004).  Although the specific downstream target genes responsible for this 
effect were not determined, this striking in vivo phenotype was an early 
demonstration that miRNAs could indeed contribute to key aspects of lymphoid 
biology. 
 Subsequently, data obtained from studying the aforementioned B cell-
specific Dicer1 knockout mouse further strengthened this notion.  The observed 
blockage in B cell development at the pro- to pre-B cell transition was determined 
to be a consequence of aberrant Bim (Bcl2l11) upregulation upon loss of 
repression by the miR-17~92 cluster; B cell-specific ablation of Bcl2l11 and 
transgenic expression of Bcl2 partially rescued the blockage, allowing some B 
cells to progress to maturity (Koralov et al., 2008).  Another miRNA, miR-150, 
has also been implicated as a regulator of immature B cell development.  
Overexpression of miR-150 in mouse HSCs blocks progression of B lymphocyte 
development beyond the pro- to pre-B cell transition; this effect is due to miR-150 
suppression of the transcription factor MYB (Xiao et al., 2007), and consistent 
with a modest miR-150-mediated effect on total MYB protein levels, this 
overexpression accurately phenocopies MYB haploinsufficiency.  Conversely, 
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conditional deletion of miR-150 allows for aberrantly high levels of MYB 
expression in developing B cells, and results in the opposite phenotype of 
accumulation of B cells in the secondary lymphoid tissue and periphery (Xiao et 
al., 2007). 
 In addition to their clear function in immature B cells, miRNAs are also 
important regulators of several aspects mature B cell development, including the 
GC reaction.  In contrast to the severe phenotype observed upon Dicer1 
knockout in immature B cells, ablation of Dicer1 specifically in mouse mature B 
cells via does not lead to a complete developmental blockage.  However, the 
equilibrium of GC formation is affected, with a greater number of marginal zone B 
cells, and a decreased number of GC follicular B cells observed in these mice 
(Xu et al., 2012).  Although the specific miRNAs involved in this effect were not 
conclusively demonstrated, as for the immature B cell Dicer knockout model, GC 
development could be partially rescued by ablation of the pro-apoptotic gene Bim 
(Xu et al., 2012).  However, through independent work, several miRNAs are 
indeed known to be involved in the control of various aspects of GC dynamics. 
 Perhaps the best studied of GC-relevant miRNA, miR-155 is highly 
expressed in mature B cells, and is induced upon BCR stimulation (Yin et al., 
2008).  Deletion of the miR-155 host gene results in impaired immunoglobulin 
affinity maturation in B cells (Rodriguez et al., 2007; Thai et al., 2007), and miR-
155 has been connected to an extensive repertoire of target genes with a diverse 
set of functions in B cell development (Basso et al., 2012).  Its target genes 
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include AICDA, the enzymatic facilitator of SHM and CSR (Dorsett et al., 2008; 
Teng et al., 2008); SPI1, CEBP, IRF8, and MYB, all important regulators of B cell 
differentiation (Basso et al., 2012; Costinean et al., 2009; Vigorito et al., 2007); 
and SHIP1, a modulator of BCR and PI3K signaling (O'Connell et al., 2009), 
among others.  Furthermore, miR-155 has recently been shown to be a direct 
target of BCL6-mediated transcriptional repression in the GC (Basso et al., 
2012), and thus is a component of the genetic network that most critically defines 
GC identity and function (Basso et al., 2010).   
 Parallel to their roles in normal development, miRNAs also have a dark side 
in B cells.  The hijacking of normal developmental pathways by tumors is a 
consistent theme of cancer biology, and pathways involving miRNA signaling are 
no exception.  The misregulation of miRNA expression is a widespread 
phenomenon in transformed cancer cells, contributing to many phenotypes 
conducive to the development or maintenance of tumors, including aberrant 
growth, resistance to apoptosis, and metastasis (Esquela-Kerscher and Slack, 
2006).  A number of miRNAs have been causally linked to the development of B 
cell leukemia and lymphoma, with many others implicated by their aberrant 
expression in cancer cells (Croce, 2009).  Each major subtype of mature B cell 
lymphoma is associated to varying degrees with altered miRNA signaling (Di 
Lisio et al., 2012; Fabbri and Croce, 2011). 
 The most thoroughly understood example of a miRNAʼs role in B cell 
oncogenesis springs from genetic investigations of chronic lymphocytic leukemia 
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(CLL).  Heterozygous or homozygous deletion of the 13q14 human chromosomal 
region, which includes the miR-15a/16 cluster, is the single most frequent genetic 
abnormality in cases of CLL (Cimmino et al., 2005).  Although long suspected to 
be important in the development of this disease, the exact role of the miRNAs 
themselves was uncertain, given the fact that clinically observed miR-15a/16 
deletion is always accompanied by alteration of their noncoding host gene, 
DLEU2, as well as typically by the alteration of adjacent protein coding genes.  
However, precise genetic dissection of this locus in mice finally confirmed 
miRNA-15a and miR-16 as the first bona fide small RNA tumor suppressors 
(Klein et al., 2010).  Deletion either of a large region flanking the miR-15a/16 host 
gene DLEU2, or of a small region including the miRNAs only, causes mice to 
develop lymphoproliferative disease or CLL, likely due to overexpression of miR-
15a/16 targets such as the cell cycle regulators CCNE1, CCND1, CCND3, as 
well as of anti-apoptotic genes such as BCL2 (Klein et al., 2010). 
 Additional examples of miRNA involvement in B cell malignancies abound.  
Burkitt Lymphomas (BL) frequently lack expression of miR-155 (Kluiver et al., 
2007), an important regulator of the mutagenic enzyme AICDA (Dorsett et al., 
2008; Teng et al., 2008).  This is of particular interest in the pathogenesis of BL, 
because miR-155 expression has been shown to suppress the occurrence of 
AICDA-dependent MYC-IGH translocations, which is the hallmark of this disease 
(Dorsett et al., 2008).  Conversely, miR-155 is frequently overexpressed in 
diffuse large B cell lymphoma (DLBCL), particularly in the activated B cell (ABC-
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DLBCL) subtype.  Although neither the cause nor the molecular consequence of 
this expression is fully understood, the level of miR-155 has potential diagnostic 
utility in distinguishing between the major subtypes of DLBCL (Di Lisio et al., 
2012). 
 Constitutive expression of a subset of the “onco-miR” cluster miR-17~92 in 
the mouse B cell lineage has been shown to be sufficient to induce 
lymphoproliferative disease (Xiao et al., 2008) and to cooperate in Myc-driven 
oncogenesis (He et al., 2005), mirroring the observation that this miRNA cluster 
is amplified in human DLBCL (Lenz et al., 2008).  Furthermore, the miR-17~92 
cluster is itself a direct transcriptional target of MYC (Chang et al., 2008), an 
oncogene that plays a key role in the transformation of a large fraction of B cell 
lymphomas; through MYC deregulation and other mechanisms, including genetic 
amplification of the 13q31 region, miR-17~92 is overexpressed in approximately 
65% of lymphomas (He et al., 2005; Lenz et al., 2008), resulting in aberrant 
downregulation of a set of targets that includes the apoptotic facilitator gene BIM 
(Ventura et al., 2008), the PI3K regulator PTEN (Ivanovska et al., 2008), and the 
cell cycle regulator p21 (CDKN1A) (Ivanovska et al., 2008). 
 In addition to gross transcriptional changes affecting miRNA expression, 
other mechanisms may potentially contribute to the disruption of miRNA signaling 
in cancer cells.  Such mechanisms include deletion or inactivation of protein 
factors that modulate miRNA activity (Kumar et al., 2009), alternative splicing of 
gene transcripts to modify the presence or absence of miRNA binding sites in the 
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3ʼUTRs of key genes (Mayr and Bartel, 2009), or modulation of miRNA 
availability by increased or decreased expression of transcripts that can compete 
for their binding (Poliseno et al., 2010; Sumazin et al., 2011).  Further work will 
determine the extent to which these mechanisms, and others, are important in 
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This chapter is adapted from Basso et al. Immunity. (2009)., and contains 
selected text and data from that published work.  As an author on this publication, 
I shared responsibility for the sequencing of small RNA libraries, and was fully 
responsible for both the PCR-based validation of novel small RNAs, and for 
experiments demonstrating co-immunoprecipitation of novel small RNAs with 
Argonaute proteins.  Additionally, I contributed to the analysis of the resulting 
small RNA sequences, specifically, the discovery that many match to tRNAs.  
This realization led to functional investigations of these small RNA, described in 




In the years prior to widespread adoption of deep sequencing technologies, there 
was substantial uncertainty regarding the extent of small RNA expression; neither 
the total number of microRNAs (miRNAs), nor the extent of their expression was 
known.  Because the majority of known miRNAs were identified by virtue of their 
abundant expression in a few cell types, we hypothesized that many tissue-
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specific miRNAs might remain unrevealed.  Therefore, to better understand the 
role of miRNAs in B cell function and lymphomagenesis, we generated short-
RNA libraries from normal human B cells at different stages of development 
(naïve, germinal center, memory) and from a Burkitt lymphoma cell line.  A 
combination of cloning, Sanger sequencing, and computational analysis identified 
178 distinct miRNAs expressed in these B cell libraries. Most notably, the B cell 
miRNome included 75 miRNAs that had not previously been reported.  Numerous 
miRNAs were expressed in a stage- or transformation-specific fashion in B cells, 
suggesting specific functional or pathologic roles.  Despite possessing many 
miRNA-like features, a large fraction of the newly identified sequences matched 
to transfer RNAs.  This finding raised the intriguing possibility that transfer RNAs 




The discovery of miRNAs is still an on-going process, with variable predictions of 
the total number of miRNAs expressed in mammalian cells ranging from one 
thousand to several thousands (Bentwich et al., 2005; Miranda et al., 2006).  The 
majority of reported miRNAs have been identified from a limited number of cell 
types or from tissues whose cellular heterogeneity may favor the identification of 
ubiquitous and abundant miRNA.  In fact, a recent report attempting to establish 
miRNA expression profiles for a large panel of mammalian tissues and cell types 
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resulted in the discovery of only 12 previously unreported human miRNA 
(Landgraf et al., 2007).  These findings supported the conclusion that most 
miRNAs are known and that the majority are ubiquitously expressed (Landgraf et 
al., 2007).  Nonetheless, additional analyses of purified cell populations have led 
to the identification of tissue- and stage of differentiation-specific miRNAs, 
suggesting that specialized miRNA expression does indeed occur (Calabrese et 
al., 2007; Cummins et al., 2006). 
Several initial observations suggest an important role for miRNAs in B cell 
function and malignancy (reviewed in Chapter 1).  Genetic manipulation in mouse 
models has demonstrated that miR-155 can affect regulation of the GC response 
through modulation of cytokine production (Rodriguez et al., 2007; Thai et al., 
2007) and by direct post-transcriptional regulation of the activation-induced 
cytidine deaminase (AICDA) (Dorsett et al., 2008; Teng et al., 2008).  miR-150 
has been shown to target MYB, a critical transcription factor involved in the 
control of B cell differentiation (Xiao et al., 2007).  In B cell lymphomas, 13q31 
amplification is associated with the overexpression of the miR-17-92 cluster, and 
its enforced expression in two different murine B cell models revealed a role in 
inducing lymphoproliferative disease (Xiao et al., 2008) and in accelerating tumor 
development (He et al., 2005).  Furthermore, the miR-15a/miR-16 cluster is 
frequently deleted in B cell chronic lymphocytic leukemia (CLL), an event that has 




As a basis for a comprehensive analysis of the role of miRNAs in B cell 
function and lymphomagenesis, this study was designed to identify the 
expressed miRNAs (miRNome) in the human mature B cell compartment, 
including naïve, germinal center (GC), and memory B cells.  By using a 
combination of cloning and computational analysis, we report the identification of 
at least 178 miRNAs representing the mature B cell miRNome, including 75 
previously unreported miRNAs.  The results show that specific miRNA signatures 
characterize normal B cell subpopulations.   The specificity of these signatures 
suggests functional roles for miRNAs in B cell differentiation and transformation. 
 
RESULTS 
Construction of Short-RNA Libraries from Human B Cell Subpopulations 
Short-RNA libraries were generated by cloning RNA fractions of 15–30nt from 
human GC, naïve, and memory B cells purified from tonsils, as well as from the 
Burkitt lymphoma (BL) cell line Ramos, which is representative of malignant 
transformation of GC B cells.  Approximately 3,500 sequences were analyzed 
from each library, corresponding to 13,788 total short RNAs (2,632 non-
redundant sequences). 
 
Mapping of Short-RNA Sequences to the Human Genome 
The cloned sequences were subjected to a computational analysis summarized 
in the flowchart illustrated in Figure 2.1.  Each cloned sequence was first 
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matched to the human genome assembly (March 2006, hg18) to retrieve the 
genomic regions from which the short RNAs originated.  One or more genomic 
locations were identified for 2086 (~80%) of the cloned sequences considering 
both perfect matches and single mismatches (Figure 2.1).  Consistent with 
previous observations, 3ʼ-end mismatches were the most common and showed a 
clear preference for A in the last position (data not shown) (Neilson et al., 2007).  
The failure of 546 short-RNA sequences to align with the human genome is likely 
due, at least in part, to errors introduced by PCR during the cloning procedure.  
However, a small subset of these short RNAs lacking a corresponding genomic 
region in Homo sapiens have been cloned with high frequencies in multiple 
libraries and showed differential expression during B cell differentiation (data not 
shown), suggesting that they may represent bona fide short- RNA species that 
cannot be mapped on the current reference genome, probably because of 
polymorphisms and/or post-transcriptional modifications.  However, given the 
difficulty of assigning genomic coordinates to these sequences, they were 
omitted from further analyses (see Discussion). 
 
Computational Prediction of Precursor and Mature microRNAs 
In order to identify novel candidate miRNAs among the cloned short RNA 
sequences, we developed a computational pipeline designed to identify potential 
miRNA precursors based on the investigation of their genomic location and 
folding characteristics (Figure 2.1).  In brief, short RNA sequences were mapped 
    
38 
to the human genome and their respective candidate genomic precursors (±90nt) 
were retrieved and analyzed for secondary structure, size and energy of the loop, 
and number of complimentary base pairs in the stem of the loop.  The prediction 
was performed on the full set of non-redundant short RNAs (2632 sequences) for 
which one or more genomic locations could be identified (Figure 2.1).  The 
analysis led to the identification of candidate miRNA precursors for 1646 short-
RNA sequences, which were then clustered allowing for (1) variability observed 
at the mature miRNA 3ʼ ends (and less dramatically at the 5ʼ ends) including 
nucleotide substitutions and deletions, and (2) the possibility of miRNA editing as 
previously reported (Kawahara et al., 2007; Luciano et al., 2004).  After 
annotating each candidate mature miRNA, those which matched mRNA, rRNA, 
tRNA, post-transcriptionally modified tRNA, and other ncRNA (yRNA, 
sn/snoRNA) sequences, and were present only once in the libraries were not 
considered further.  The remaining sequences were still considered miRNAs 
based on criteria (identification of genomic loci consistent with a pre-miRNA, 
length, recurrence, differential expression, detection in the Argonaute complex) 
that suggest their existence as bona fide miRNA.  Based on the miRNA length 
distribution of the Homo sapiens miRBase database (v11.0), only mature 
candidate miRNAs of length 17–28nt were considered. 
Overall, the analysis identified 178 mature miRNAs, of which 103 were 
known and 75 were to our knowledge not previously reported.  Computational 
prediction of precursor miRNAs (pre-miRNA) identified 114 precursors already 
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reported to potentially code for the 103 known mature miRNA, and 274 genomic 
locations containing novel candidate pre-miRNA associated with the 75 
previously unreported and 8 known mature miRNAs (Figure 2.2). 
A sizeable number of sequences (334) aligned to genomic regions that did 
not fulfill the criteria for miRNA precursors (Figure 2.1).  About 80% of these 
sequences were annotated or cloned only once and may represent degradation 
products originating from other RNA species (Figure 2.1).  The remaining 58 
sequences, however, mapped to genomic regions that lack annotation and may 
therefore represent a part of the transcriptome whose functions are unknown.  
Interestingly, several of these unannotated sequences were cloned multiple times 
and showed differential expression across libraries, suggesting that they may 
represent short RNAs with characteristics distinct from those currently recognized 
in ʻʻclassicʼʼ miRNAs. 
 
MicroRNA Abundance 
Previously reported miRNAs appeared to be generally more abundant than newly 
discovered miRNAs.  Approximately 50% of previously reported miRNAs 
appeared in the libraries with more than 10 occurrences compared to 29% of the 
newly discovered miRNAs (Figure 2.3a).  Moreover, 48% of known miRNAs were 
expressed at all stages of mature B cell development, whereas newly identified 
miRNAs showed a more distinct stage specificity (Figure 2.3b), consistent with 
the notion that presently known miRNAs are mostly representative of ubiquitously 
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expressed miRNAs (see Discussion). 
 
Validation of Previously Unreported microRNAs 
All 75 newly identified miRNAs were investigated by RT-PCR analysis in order to 
independently validate their existence in vivo in B cell lines and cells isolated 
from tonsils.  Positive results were obtained in 66 of the cases (see Figure 2.4a 
for representative results).  Eighteen previously unreported miRNAs were also 
tested by RNA blot analysis and 11 were detectable (Figure 2.4b), either from 
total cellular RNA or upon enrichment for the short-RNA fraction.  Overall, 88% of 
the newly cloned and computationally validated miRNAs were detectable by RNA 
blot and/or RT-PCR.  The validation process also led to the identification of 
numerous miRNA that are differentially regulated either in normal versus 
transformed cells (see examples CU-1440, CU-1241, CU-1276, and CU-1137 in 
Figure 2.4) as well as during the GC reaction (see below, Figure 2.6). 
In order to gain preliminary evidence as to the functionality of the 
previously unreported miRNAs, a small set of miRNAs that were fully validated at 
the expression level was tested for incorporation in the functional miRNA-mRNA 
complex by co-immunoprecipitation with Ago2 proteins (Mourelatos et al., 2002).  
The results showed that the RNA fraction associated with the Ago complex was 
indeed enriched for each of the four tested previously unreported miRNAs (Figure 
2.5), consistent with entry into the expected miRNA functional pathway. 
In summary, previously unreported miRNAs identified by cloning and 
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computational analysis were validated at the expression level by multiple 
detection methods.  For the small subset of sequences tested, incorporation in 
the Ago complex suggests that they are biologically functional. 
 
Distinct microRNA Signatures in Normal B Cell Subpopulations 
In order to further investigate whether specific miRNA regulation occurred in 
normal B cell development or in transformed cells, we examined miRNA 
representation in the libraries constructed from naïve, GC, and memory B cells, 
as well as from the Ramos BL cell line.  Differential expression of numerous 
known and newly identified miRNAs was evident during B cell differentiation and 
GC transit as shown by hierarchical clustering by miRNA frequencies (defined as 
the fraction of the total pool of cloned miRNAs represented by a given miRNA in 
a library) obtained from the cloning data (Figure 2.6a).  Naïve and memory B 
cells appeared similar, sharing a large fraction of the most abundant miRNAs.  
Conversely, centroblasts showed a more distinct miRNA profile, with a sizeable 
fraction of abundant miRNAs specifically expressed in the CB library.  Some 
miRNAs were expressed in the GC-derived Ramos cells, but not in normal GC B 
cells, or vice versa in the normal but not in the tumor cells, suggesting that, as 
expected, malignant transformation affects miRNA expression. 
To independently validate the results of the cloning experiment, we also 
performed miRNA expression profiling of GC, naïve, and memory B cells (six 
donors each) by using a commercial microarray representative of 723 known 
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human miRNAs (miRBase v.10.1).  The Spearman correlation between cloning 
and microarray data is 0.7 corresponding to a p value < 3.9e-28.  Each B cell 
population showed a distinct miRNA expression profile.  Consistent with the 
cloning data (Figure 2.6a), GC B cells appeared to be quite distinct from naïve 
and memory B cells, which instead shared expression of a large fraction of 
miRNAs (Figure 2.6b).  The expression of several miRNAs was tested by qRT-
PCR analysis, which confirmed that the microarray data were quantitatively 
accurate (data not shown).  Overall, these results show that the GC reaction is 
characterized by the specific expression of multiple miRNAs. 
 
An intriguing class of microRNA-like small RNAs matching to tRNA 
We note that many of the validated miRNAs display similarity to post-
transcriptionally modified tRNAs, suggesting that they may derive from loci with 
tRNA homology or by direct processing of tRNAs.  Of the 75 novel miRNAs 
identified in this study, 44 match to tRNA, accounting for 88% of the total counts 
attributed to novel sequences.  However, the expression of 41 out of 44 tRNA-
matching sequences were successfully validated by RT-PCR, with 9 
independently verified by RNA blot (Figure 2.4).  Moreover, 4 out of 4 such 
sequences tested were positively enriched in immunoprecipitations of Ago2 
protein, strongly suggesting that, regardless of origin, these small RNAs can act 
as functional miRNAs (Figure 2.5). 
A thorough search for all possible tRNA-matching small RNA fragments in 
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the naïve, germinal center, memory, and Ramos B cell libraries, irrespective of 
computational filters for cloning frequency or matches to annotated RNA species, 
yields 129 distinct sequences that can be roughly classified into four groups 
(Figure 2.7a):  those matching precisely to the post-transcriptionally modified 3ʼ 
terminus, called tRF-3s; those matching to the 5ʼ terminus, called tRF-5s; those 
matching to the mature tRNA, but not precisely lining up with either terminus, 
called tRF-4s; and those matching to the 3ʼ trailing fragment generated by ELAC1 
cleavage of the tRNA primary transcript, called tRF-1s (“tRF” nomenclature 
adapted from [Lee et al. 2009]).  In each of the four libraries examined, tRF-3 
sequences are the most common (Figure 2.7b).  Ramos cells also express 
abundant levels of tRF-1 sequences (Figure 2.7b). 
From this data, it is not possible to determine whether these sequences 
are derived directly from tRNA, or are expressed from genomic regions of tRNA 
homology.  Further experiments are therefore necessary to elucidate the 
biogenesis pathways leading to the expression of these small RNAs, and to 
understand their functional role in B cells. 
 
DISCUSSION 
The combination of cloning procedures and computational tools used in this 
study led to the identification of a large fraction of miRNA expressed during B cell 
differentiation.  These included 75 previously unreported miRNAs, as well as a 
number of short RNAs not fulfilling current criteria for miRNAs.  These findings 
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have general implications for the understanding of the total miRNA content of the 
human genome as well as for future studies on the role of miRNAs in B cell 
differentiation, function, and lymphomagenesis. 
The discovery of 75 previously unreported miRNAs expressed in normal 
and/or malignant B cells is in contrast with a previous study that reported the 
discovery of only 12 new human miRNA (Landgraf et al., 2007) from an analysis 
of a large panel of different organ systems and cell types and suggested that 
most miRNAs have already been identified and are ubiquitously expressed 
(Landgraf et al., 2007).  These discordant results and conclusions may be due (1) 
to the higher number of clones per library sequenced in this study (3500 versus 
1300 on average in [Landgraf et al. 2007]), which allowed the detection of low-
abundance miRNA species, and (2) to the criteria applied in the miRNA 
identification that do not include conservation and allow consideration of 
repetitive elements or of specifically processed sequences with matches to 
previously annotated noncoding RNA.  However, because 88% of the previously 
unreported miRNAs have been independently detected by RT-PCR and/or RNA 
blot analyses, our cloning and computational approach is largely validated. 
The stage-specific expression of various miRNAs strongly suggests highly 
specialized regulatory functions in B cell biology.  The miRNAs specifically 
associated with GC or non-GC B cells by either cloning or miRNA expression 
profiling have not been previously reported in B cell differentiation with the 
exception of miR-150 (Xiao et al., 2007).  For example, the miR-199 and miR-125 
    
45 
families as well as miR-138 show a distinct expression in GC B cells although 
none of these miRNAs has been investigated for a role in this cell compartment.  
The extent of post-transcriptional regulation added by miRNAs will be fully 
uncovered only in the context of the complex network of cellular interactions 
(Basso et al., 2005), which will require the integration of large-scale gene and 
miRNA expression data. 
miRNA expression can be affected by malignant transformation.  For 
instance, the miR-17-92 cluster, previously reported as a potential oncogene (He 
et al., 2005), was found overexpressed in Ramos cell line compared to GC B 
cells.  Moreover, several miRNAs (i.e., CU-1137, CU-1148) show expression in 
Ramos cells and in several additional BL cell lines (data not shown), but not in 
their normal GC counterpart. Vice versa, as observed for the miR-199 family, the 
expression of some miRNAs is lost in the tumor cells. The data herein represents 
a useful basis to investigate whether lymphoma-associated chromosomal lesions 
affect genomic regions associated with miRNA expression. 
Finally, the differences in miRNA expression profile between GC and non-
GC B cells resembled those observed by expression profiling of coding genes 
(Klein et al., 2003), consistent with the previous observation that miRNA profiling 
may be equally or more informative in discriminating tumor phenotypes (Calin et 
al., 2005; Lu et al., 2005). This suggests that miRNA expression profiling, 
especially if including novel B cell-specific miRNAs, may be useful in the 
differential diagnosis of lymphoid malignancies. 
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The expanded B cell miRNome described here represents a resource that 
can be used to identify miRNAs expressed during the GC transit as well as 
specific differences in miRNA expression in normal versus lymphoma cells, and 
which can guide studies to unveil the function of miRNAs in normal B cell 
development and lymphomagenesis. 
 
EXPERIMENTAL PROCEDURES 
Generation of short-RNA libraries 
Purification of naïve, memory and GC B cells was performed as previously 
reported (Klein et al., 2003) using magnetic cell sorting of mononucleated cells 
obtained from human tonsils. Total RNA was purified using the Trizol Reagent 
(Invitrogen) following the manufacturerʼs indications. The short-RNA libraries 
were generated using an established protocol described in detail in (Lau et al., 
2001). Briefly, total RNA was separated on 15% polyacrylamide gel and the 
fragment corresponding to 15-30 nucleotides length was excised. The purified 
small RNAs were linked to adaptor oligonucleotides and gel purified. Upon 
adaptor ligation, RNA was reverse transcribed and cDNA was PCR amplified and 
cloned into pCR2.1-TOPO vector (Invitrogen). Sequencing was performed on 
colony PCR amplicons.  
 
Computational identification of precursor and mature miRNAs 
    
47 
The bioinformatics miRNA analysis pipeline includes: (a) identification of short-
RNAs from each library, (b) identification of exact and partial matches of the 
short-RNA sequences to the human genome, (c) testing each short-RNA 
genomic region for compatibility with hairpin secondary structures, (d) clustering 
genomic regions to predict mature miRNAs, (e) annotating and filtering short-
RNAs and miRNAs candidates, (f) estimation of predicted miRNA frequencies in 
the libraries and (g) clustering short-RNAs that do not support miRNA 
candidates. The details are reported in the Supplemental Experimental 
Procedures. 
 
miRNA expression profiling 
The miRNA expression profiles were generated using the Human miRNA 
Microarray kit (Agilent Technologies) that allows detection of 723 known human 
(miRBase v.10.1) and 76 human viral miRNAs, following the manufacturerʼs 
indications. Analysis of raw data was performed using the Feature Extraction 
Software 9.5.3.1 (Agilent Technologies). The dendrograms (Figure 2.6) were 
generated using a hierarchical clustering algorithm based on the average-linkage 
method (Eisen et al., 1998; Hartigan, 1975) and Spearmanʼs correlation as 





Small RNA fractions were purified using the Trizol Reagent (Invitrogen) and the 
PureLink miRNA Isolation Kit (Invitrogen), following the manufacturerʼs 
indications. RT-PCR was performed as previously described (Sharbati-Tehrani et 
al., 2008).  Briefly, miRNA sequences were reverse-transcribed from 50ng short-
RNA using Superscript III First Strand Synthesis Kit (Invitrogen), in the presence 
of 0.2µM RTFS primer (miRNA-specific primers).  1/10th of the cDNA volume was 
then used as template for 34 cycles of PCR amplification in the presence of 4nM 
SS primer (miRNA-specific primers) and 0.4µM each of MPF and MPR universal 
primers. PCR products were separated on 12% non-denaturing polyacrylamide 




Total RNA and small RNA fractions were purified using the Trizol Reagent 
(Invitrogen) and the PureLink miRNA Isolation Kit (Invitrogen), respectively, 
following the manufacturerʼs indications. Electrophoresis was performed on 15% 
denaturing polyacrylamide gel and then RNA was transferred on Duralon UV 
membrane (Stratagene) using a semidry transfer apparatus. Pre-hybridization 
and hybridization were performed in 5X SSC, 20mM Na2HPO4 pH7.2, 7% SDS, 
3X Denhardtʼs Solution. Oligonucleotide probes were [g-32P]-ATP labeled by 
polynucleotide kinase (Fermentas).  After over-night hybridization, membranes 
were washed at the same temperature in 3X SSC, 25mM NaH2PO4 pH 7.5, 5% 
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SDS, 10X Denhardtʼs Solution for 15-20ʼ and in 1X SSC, 1% SDS for 5ʼ. Images 
were obtained by exposure to phosphoimager cassette and acquisition by Storm 
840 Phosphoimager (Molecular Dynamics) and by film exposure for 
approximately 2 weeks. 
 
Supplemental Experimental Procedures 
Additional information on computational procedures can be obtained from the 
supplemental materials published in (Basso et al. 2009). 
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Figure 2.1.  Computational analysis of short RNA libraries. 
Short RNA sequences were analyzed according to their ability to match to the 
human genome, the folding characteristics of their precursor regions, and their 





Figure 2.2.  Predicted precursor and mature miRNAs. 
The number of predicted precursor miRNAs (pre-miR) and mature miRNA 
(mature-miR) are plotted independently for each library and overall.  The 
sequences matching miRNAs deposited in the miRBase database (v.11.0) are 









Figure 2.3.  Relative abundance of miRNome elements. 
(A) Frequencies of previously reported (known) and newly identified (new) 
miRNAs as occurring in naïve, centroblasts, memory, and Ramos cells.  Single 
occurrence miRNAs are not included. 
(B) Number of miRNAs cloned multiple times and identified in naïve, 
centroblasts, and memory B cells.  A larger overlap is observed for known as 






Figure 2.4.  Detection of previously unreported miRNAs by RT-PCR and 
Northern Blot. 
(A) Representative results of RT-PCR detection of miRNA in Ramos cell line 
tonsil cells.  miR-30c was used as loading control. 
(B) Detection of mature miRNA species by RNA blot in Ramos cell line, 
centroblasts (CB), and naïve B cells isolated from human tonsils.  RNU44 was 
used as loading control. 
(C) RNA blot images displaying both the mature (20-25nt) and the precursor (60-
80nt) miRNA species.  miRNA expression can be regulated at the transcriptional 
level (top) or at the processing level (bottom) when intermediate forms (pre-
miRNA) are generated by are not fully processed to mature miRNA.  The naming 





Figure 2.5.  Novel miRNAs co-immunoprecipitate with Argonaute protein. 
Novel miRNAs as well as known (miR-16) are enriched in Ago2 
immunoprecipitations (IP) as compared to control IgG immunoprecipitates.  Other 
small RNA species not involved in miRNA signaling (5s rRNA) are not enriched in 







Figure 2.6.  MiRNA expression profiling distinguishes developmental 
stages of normal as well as malignant B cells. 
(A) Unsupervised clustering performed via miRNA frequency values (≥ 0.08) 
calculated as the fraction of the total pool of cloned miRNAs represented by a 
given miRNA in a library. 
(B) Unsupervised clustering of microarray-based miRNA expression profiles 
distinguishes centroblasts, naïve, and memory B cells purified from tonsil tissue 









Figure 2.7.  Many novel miRNAs match to tRNA. 
(A) Re-analysis of cloned small RNA sequences for tRNA-matching fragments 
reveals four classes:  those matching precisely to the post-transcriptionally 
modified 3ʼ terminus (tRF-3s), those matching to the 5ʼ terminus, called (tRF-5s), 
those matching to the mature tRNA, but not precisely lining up with either 
terminus, called (tRF-4s), and those matching to the 3ʼ trailing fragment 
generated by ELAC1 cleavage of the tRNA primary transcript (tRF-1s). 
(B) Relative abundance of tRF classes within centroblast (GC), naïve, memory, 
and Ramos libraries.  Normal B cell libraries primarily contain tRF-3 sequences, 
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Sequencing studies from several model systems have suggested that diverse 
and abundant small RNAs may derive from tRNA, but the function of these 
molecules remains undefined.  Here we demonstrate that one such tRNA-derived 
fragment, cloned from human mature B cells and designated CU1276, in fact 
possesses the functional characteristics of a microRNA, including a Dicer-
dependent biogenesis, physical association with Argonaute proteins, and the 
ability to repress mRNA transcripts in a sequence-specific manner.  Expression 
of CU1276 is abundant in normal germinal center B cells but absent in germinal 
center-derived lymphomas, suggesting a role in the pathogenesis of this disease.  
Furthermore, CU1276 represses endogenous RPA1, an essential gene involved 
in many aspects of DNA dynamics, and consequently, expression of this tRNA-
derived microRNA in a lymphoma cell line suppresses cellular proliferation.  
These results establish that functionally active microRNAs can derive from tRNA, 






In recent decades, sequencing studies have uncovered a diverse menagerie of 
small RNA molecules expressed in eukaryotic cells, among which microRNAs 
(miRNAs) are perhaps the single best-understood subclass.  miRNAs guide the 
binding of Argonaute-containing induced silencing complexes (miRISC) to the 3ʼ 
untranslated region (3ʼUTR) of genes bearing partially complementary sites, and 
are typically expressed from within the introns of protein coding genes or as part 
of long non-coding RNA transcripts (He and Hannon, 2004).  However, recent 
work has demonstrated that miRNAs can also arise from previously unanticipated 
non-canonical pathways.  Specifically, miRNAs can be generated in a DROSHA-
independent (Bogerd et al., 2010; Ladewig et al., 2012; Ruby et al., 2007) or 
DICER1-independent manner (Cheloufi et al., 2010; Cifuentes et al., 2010), and 
have been demonstrated to arise from cleavage of otherwise functional non-
coding RNA molecules, such as small nucleolar RNA (Ender et al., 2008). 
Previously, we reported cloning and sequencing of small RNAs purified 
from human naïve, germinal center (GC), and memory B cells, as well as from 
the Burkitt lymphoma cell line Ramos (Basso et al., 2009).  In addition to 
observing known and novel miRNAs, we noted an intriguing class of abundantly 
expressed small RNAs whose sequences perfectly matched either to mature or 
to precursor tRNA transcripts.  Several other groups have reported similar small 
RNA species expressed in a variety of human cell types (Burroughs et al., 2011; 
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Cole et al., 2009; Haussecker et al., 2010; Kawaji et al., 2008; Lee et al., 2009) 
as well as in other organisms (Babiarz et al., 2008; Couvillion et al., 2010; Hsieh 
et al., 2009).  However, the functional role of these small RNAs, and in particular 
the possibility that they may act as miRNAs, has not yet been adequately 
addressed.  Here we show that at least one such sequence, designated CU1276, 
indeed functions as a miRNA. 
 
RESULTS 
CU1276 is a DICER1-dependent tRNA fragment expressed in mature B cells 
Taken together, previous reports (Cole et al., 2009; Haussecker et al., 2010; Lee 
et al., 2009) define a minimum of three distinct categories of tRNA fragment:  
those matching to the 5ʼ end of mature tRNA (tRF-5), those matching to the 3ʼ 
end of mature tRNA (tRF-3), and those matching to the 3ʼ end of precursor tRNA 
transcripts (tRF-1).  Further analysis of our published small RNA sequencing data 
(Basso et al., 2009) suggested that amongst these classes, tRF-3s are by far the 
most abundant variety expressed in mature B cells; therefore, in order to 
investigate the biological function of these molecules, we sought to characterize 
a representative sequence of the tRF-3 class, designated CU1276. 
CU1276 is a 22nt small RNA (5ʼ-TCGATTCCCGGCCAATGCACCA-3ʼ) 
differentially expressed in three stages of mature B cell differentiation and one 
GC-derived lymphoma cell line, cloned most frequently in normal GC B cells 
(Figure 3.1a).  Despite its miRNA-like size, CU1276 is a perfect match to the 
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post-transcriptionally modified 3ʼ end of at least six annotated human tRNAs 
(Chan and Lowe, 2009) (Figure 3.1b).  In order to clarify the relationship between 
CU1276 and tRNA, we cloned a CU1276-matching tRNA locus into an 
expression vector, and transiently transfected this vector into HEK-293T cells 
(293T).  Northern Blot analysis of these cells revealed a clear increase in both 
the mature tRNA and a 22nt band co-migrating with the endogenous fragment 
observed in B cells (Figure 3.1c), suggesting that CU1276 is indeed tRNA-
derived.  We also confirmed CU1276 expression from a second, independent 
Gly(GCC) tRNA locus, and ruled out the possibility of expression from a 
candidate precursor genomic locus (Basso et al., 2009) closely matching the 
CU1276 sequence, but not encoding a tRNA (Figure 3.2). 
tRNA do not meet the structural criteria of a classical Dicer substrate 
(Hammond, 2005); nonetheless, due to the observed similarities in size between 
CU1276 and Dicer-dependent miRNA, we hypothesized that this enzyme could 
be involved in CU1276 biogenesis.  Therefore, we transiently overexpressed a 
CU1276-matching tRNA in 293T cell lines stably expressing either a control 
shRNA or a pool of three Dicer-targeting shRNA.  Northern Blot analysis revealed 
that knockdown of Dicer was sufficient to reduce production of CU1276, 
regardless of an accumulation of mature tRNA (Figure 3.1d).  Indeed, CU1276 
was more sensitive to Dicer knockdown than the canonical miRNA miR-16 
(Figure 3.1d).  This evidence strongly supports a Dicer-dependent cleavage step 
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in the biogenesis of CU1276, which may be a general feature of fragments 
derived from mature tRNA. 
 
CU1276 associates with all four human Argonaute proteins, and functions 
as a microRNA 
As a prerequisite for investigating a possible miRNA-like function of CU1276, we 
sought to determine whether this small RNA was physically associated with 
Argonaute proteins.  Utilizing a previously published antibody with reactivity 
against all four human Argonaute proteins (Nelson et al., 2007), we purified 
Argonaute-associated RNAs from the B cell line RIVA; QRTPCR analysis of the 
co-precipitated RNA confirms that CU1276 is indeed enriched in the pan-Ago 
immunoprecipitation (IP) fraction relative to a control IP (Figure 3.3a).  Based on 
this confirmation of Argonaute binding, we sought to dissect CU1276 binding 
affinity for each individual Argonaute protein through expression and IP of HA-
tagged versions of human AGO1, AGO2, AGO3, and AGO4 in 293T cells.  
CU1276 is enriched in the IP fractions of all four Argonaute proteins relative to 
the HA-EGFP control, suggesting that it is specifically incorporated into silencing 
complexes containing each one of the human Argonautes (Figure 3.3b).  The 
dynamics of this interaction seem to be influenced by the availability of 
unoccupied Argonaute complexes, given that the magnitude of CU1276 
enrichment in AGO1 complexes increased proportionally with total levels of this 
protein, meeting and eventually exceeding the enrichment of the canonical 
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miRNA miR-16 at high levels of AGO1 expression (Figure 3.3c).  Thus, similar to 
canonical miRNA, CU1276 is incorporated into endogenous Argonaute 
complexes. 
Given its demonstrated binding to the functional effectors of miRNA 
signaling, we tested the effect of CU1276 on a firefly luciferase reporter bearing 
two antisense binding sites in its 3ʼUTR.  Because overexpression of full-length 
tRNA inevitably produces a complex mixture of RNA molecules, including a 
previously reported ~34nt 5ʼ tRNA fragment capable of broadly repressing 
translation (Ivanov et al., 2011), we also cloned CU1276 into a miRNA hairpin in 
order to investigate its activity in a context free from confounding factors.  
Expression of either the tRNA or the hairpin was indeed sufficient to repress the 
antisense reporter (Figure 3.3d).  We noted that under standard conditions, the 
potency of tRNA-delivered CU1276 was less than that of hairpin-delivered 
CU1276; however, simultaneous expression of exogenous AGO2, the Argonaute 
family member whose slicer activity enables potent repression of mRNAs bearing 
a perfect antisense site (Liu et al., 2004), facilitated tRNA-mediated repression at 
comparable levels (Figure 3.3d).  While these data are potentially consistent with 
a lower affinity for Argonaute proteins or a different distribution among 
Argonautes as compared to canonical hairpin-derived miRNA, they nonetheless 
prove that the tRNA-derived CU1276 can repress mRNA targets in an 




CU1276 is downregulated in lymphoma cell lines and primary biopsies 
Formation of GC structures is a crucial step in the B cell-mediated adaptive 
immune response, and GC cells are the cell of origin for the majority of B cell 
lymphomas (Klein and Dalla-Favera, 2008).  Initial small RNA sequencing and 
Northern Blot analysis suggested that CU1276 is abundantly expressed in 
normal GC B cells, but is low in at least one GC-derived lymphoma cell line 
(Figure 3.1a, b).  To expand these findings, we assessed CU1276 by QRTPCR in 
normal GC B cells and a panel of GC-derived lymphoma cell lines.  Strikingly, 
only normal GC B cells efficiently expressed CU1276, while the entire panel of 
cell lines displayed low levels (Figure 3.4a).  Additionally, sequencing of small 
RNAs from a panel of normal GC B cells (n=4) and diffuse large B cell lymphoma 
(DLBCL) primary biopsies (n=25) revealed a binary pattern of CU1276 
expression, with CU1276 almost completely absent in tumor cells (Figure 3.4b). 
Although the cause of this strong differential expression cannot be directly 
determined from this data, the Gly(GCC) tRNA from which CU1276 is derived 
can be found in at least six distinct genomic loci (Figure 3.1b), making it an 
unlikely candidate for genetic deletion.  Indeed, each cell line tested expresses 
roughly equal levels both primary tRNA transcript and the mature, post-
transcriptionally modified form of the tRNA from which CU1276 is derived  
(Figure 3.5), suggesting that the observed decrease in CU1276 production in 




CU1276 represses a set of endogenous genes, including RPA1 
Based on a well-validated method for prediction of miRNA targets (Lim et al., 
2005), we sought to identify genes both significantly downregulated by CU1276 
expression and computationally predicted to contain CU1276 binding sites in 
their 3ʼUTR.  We anticipated that expression of Gly(GCC) tRNA was likely to 
induce changes in gene expression due to CU1276-independent effects on 
translation; therefore, in order to focus on the most physiologically relevant 
CU1276-specific targets, we compared expression profiles from 293T cells 
transfected with empty, tRNA-expressing, or CU1276 hairpin-expressing vectors.  
This analysis revealed a modest, but statistically significant (Hypergeometric test, 
p<1E-40) overlap between the downregulated probes (threshold p<0.05) in the 
two experimental groups (~13% of tRNA-downregulated genes, and ~15% 
hairpin-downregulated genes; Hypergeometric test, p<1E-40) (Figure 3.6a), thus 
confirming that tRNA-delivered and hairpin-delivered CU1276 do exert a similar 
effect on at least a subset of mRNA.  Furthermore, transcripts predicted to 
contain CU1276 binding sites by the miRNA target prediction algorithm 
TargetScan (Lewis et al., 2005) were significantly enriched (Hypergeometric test, 
p=8.6E-8) in the union of genes downregulated by tRNA and/or hairpin 
expression (Figure 3.6b), suggesting that a significant fraction of these 




To focus on the highest-confidence predictions, we narrowed our attention 
to those genes a) significantly downregulated in both tRNA- and in hairpin-
expressing cells, b) predicted by TargetScan to contain CU1276 binding sites, 
and c) expressed in the physiological site of CU1276 expression, GC B cells.  
Three genes met these criteria, and all three were tested as targets for CU1276. 
Two of these genes, WHSC1L1 and STAG2, showed either no response, 
or an ambiguous response to CU1276 expression (Figure 3.6c, d).  In contrast, 
CU1276 expression via either tRNA or hairpin was sufficient to significantly 
(Studentʼs t-test, p=3.9E-5 and p=8.2E-5, respectively) repress a reporter bearing 
the 3ʼUTR of the RPA1 gene (Figure 3.7a).  Mutation of the lone predicted 
CU1276 binding site rendered the reporter immune to this repression, confirming 
that the interaction is direct (Figure 3.7a).  Consistent with this result, transient 
expression of CU1276 by either tRNA- or hairpin-mediated delivery repressed 
endogenous RPA1 protein in 293T cells while leaving another RPA complex 
member, RPA2, unchanged (Figure 3.7b, 3.8a).  CU1276 expression had 
minimal effect on RPA1 mRNA levels as measured by qRT-PCR (Figure 3.8b), 
suggesting that in this cellular context, CU1276-mediated repression of RPA1 is 
primarily at the translational level.  In further support of this interaction, we 
constructed a stable B cell lymphoma line carrying a doxycycline-inducible vector 
encoding for the CU1276 hairpin, induction of CU1276 repressed both 
endogenous RPA1 protein and RPA1 mRNA relative to control cells (Figure 3.7b, 
3.8c, d).  Thus, RPA1 is a bona fide target of the tRNA-derived miRNA CU1276. 
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Based on our observation of strongly differential CU1276 expression 
between normal GC B cells and GC-derived lymphomas (Figure 3.4a, b), we 
hypothesized that RPA1 protein might be de-repressed in cell types lacking 
CU1276.  Consistent with this hypothesis, the majority of tested cell lines express 
higher levels of RPA1 relative to normal GC B cells (Figure 3.7c).  Although 
sufficient material was not available to directly assess RPA1 protein levels in the 
primary lymphoma biopsies, based on the high levels of RPA1 observed in cell 
lines, we speculate that loss of CU1276 expression may also contribute to 
misregulation of RPA1 in the context of primary lymphomas. 
 
CU1276 suppresses proliferation in an RPA1-dependent manner 
RPA1 has a number of well-characterized roles in DNA dynamics, including in 
the replication and repair of DNA during S phase (Haring et al., 2008).  We 
therefore hypothesized that through repression of RPA1, CU1276 might influence 
cellular proliferation. 
Indeed, stable expression of CU1276 in a Burkitt Lymphoma cell line 
modestly but significantly reduces the proliferation rate of these cells by 96 hours 
post-induction (Figure 3.9a).  Importantly, restoration of RPA1 protein expression 
to wild type levels through simultaneous induction of exogenous RPA1 
significantly rescues this growth impairment (Figure 3.9a, b), confirming that the 
repressive interaction between CU1276 and endogenous RPA1 contributes to 
this phenotype.  RPA1 expression completely rescues the CU1276-induced 
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growth phenotype at 96 hours (Figure 3.9b).  At 120 hours and 144 hours, 
however, the growth of these cells represents only a partial rescue of the 
CU1276-induced phenotype; the cell number at these time-points is significantly 
higher than that of cells expressing CU1276 without RPA1 co-expression, but is 
nonetheless significantly lower than controls expressing GFP only (Figure 3.9a).  
The inability of RPA1 expression to fully restore normal growth at later time-




An increasing body of literature supports the existence of highly abundant tRNA 
fragments of a miRNA-like size in a variety of cell types (Babiarz et al., 2008; 
Burroughs et al., 2011; Cole et al., 2009; Couvillion et al., 2010; Haussecker et 
al., 2010; Hsieh et al., 2009; Kawaji et al., 2008; Lee et al., 2009), but despite 
several lines of speculation, no conclusive evidence of their function has yet been 
shown.  Our data demonstrates that despite its derivation from the 3ʼ end of a 
mature tRNA (Figure 3.1c), the small RNA CU1276 has all of the structural and 
functional characteristics of a miRNA, including a Dicer-dependent biogenesis 
(Figure 3.1d) and binding to all four human Argonaute proteins (Figure 3.3a-c).  
CU1276 is furthermore capable of guiding repression to both artificial antisense 




In addition to their classical role in delivering amino acids to nascent 
peptide chains, tRNAs and tRNA fragments have the capacity to regulate a 
surprising range of cellular processes, including translational efficiency under 
stress conditions (Ivanov et al., 2011), mitochondrial-mediated apoptosis (Mei et 
al., 2010), and oncogenic transformation (Marshall et al., 2008).  The data 
presented here further extend the regulatory repertoire of tRNA, and greatly 
expand the pool of candidate miRNAs, by demonstrating that a tRNA fragment 
can post-transcriptionally regulate endogenous genes in a sequence-specific, 
miRNA-like fashion.   
Interestingly, we observe that the tRNA-derived microRNA CU1276 is 
strongly downregulated in GC-derived lymphomas relative to their cell of origin 
(Figure 3.4a, b).  Given that mature Gly(GCC) tRNA expression is largely 
constant between samples with highly discordant CU1276 levels (Figure 3.5 and 
Figure 3.4a), the defect in CU1276 biogenesis is likely to lie at the level of 
DICER1 cleavage.  However, with only one exception (HBL1), all tested 
lymphoma cell lines express abundant DICER1 protein (Figure 3.7c), suggesting 
that a more complex mode of regulation, such as differences in post-
transcriptional modifications that might protect the tRNA from processing (Blanco 
et al., 2011), is likely to be responsible for the observed differences.  Further 
investigation of the factors regulating CU1276 biogenesis will help to shed light 
on the upstream cause of this repression in cancer cells, while validation of 
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additional CU1276 targets will help to clarify its full downstream biological 
consequences. 
As proof of principle for its ability to regulate endogenous target genes, we 
have demonstrated that CU1276 represses endogenous RPA1 (Figure 3.7a, b).  
RPA1 is an essential gene for many aspects of DNA dynamics, including 
replication.  Consequently, stable CU1276 expression in a Burkitt Lymphoma-
derived cell line results in an RPA1-dependent suppression of their proliferation 
rate (Figure 3.9a, b).  This result, combined with the observed downregulation of 
CU1276 levels in lymphoma cell lines and biopsies (Figure 3.4a, b) suggests that 
loss of CU1276 expression may confer a growth advantage to malignant cells. 
In addition to its requirement for DNA replication, RPA1 has a GC-specific 
role in facilitating AICDA-mediated mutagenic processes (Chaudhuri et al., 2004; 
Yamane et al., 2011).  Based on our results, physiological expression of CU1276 
in the GC may contribute to fine-tuning of RPA1 levels in GC B cells, and might 
thereby indirectly influence DNA replication, somatic hypermutation, and class-
switch recombination. 
Much remains to be elucidated regarding the biogenesis and function of 
CU1276 and similar tRF molecules, but the validation of CU1276 as a miRNA 
establishes a clear regulatory potential for a large fraction of the abundant tRNA 
fragments expressed in many cell types.  Further investigation may reveal that 





MATERIALS AND METHODS 
Cell culture and transfection 
293T cells were maintained in DMEM supplemented with 10% FBS and 1% 
Penicillin/Streptomycin.  All B cell lines were maintained in IMDM supplemented 
with 10% FBS and 1% Penicillin/Streptomycin. Transfection of 293T cells was 
achieved by standard calcium phosphate precipitation, or by PEI-based 
transfection, as previously described (Ehrhardt et al., 2006). 293T-shCtrl and 
293T-shDICER stable cell lines were established by transfection with pLKO-
based vectors (see Supplementary Methods for details of plasmids and cloning 
information) followed by selection for 4 days with 2μg/ml puromycin.  P3HR1 
stable cells were established by electroporation of exponentially growing cells 
with 5pmol of pRTS1-GLSVP-based vectors according to standard protocol.  
After a 48hr recovery in IMDM supplemented with 20% FBS, cells were selected 
with 0.5μg/ml puromycin for 4 days.  Induction of expression from stable P3HR1 
cells was achieved by addition of doxycycline to growth media at a concentration 
of 100ng/ml.  DNA damage response of stable P3HR1 cell lines was assayed by 
pre-induction with doxycycline for 24 hours, followed by treatment with 0μm, 
1μM, 2μM, or 10μm concentrations of Etoposide (Sigma) for 3 hours.  
 
Northern blot and QRTPCR 
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Total RNA was purified with Trizol Reagent (Invitrogen) according to 
manufacturerʼs indications.  Northern blot was performed as previously described 
(Basso et al., 2009), using 30μg of total RNA from each sample.  
Prehybridization, hybridization, and washing were performed at 55°C.  For 
CU1276 and tRNA detection, 5ʼ-TGGTGCATTGGCCGGG-3ʼ probe was [γ-
32P]ATP labeled by polynucleotide kinase (Fermentas).  Images were obtained by 
exposure to film for 24-48 hours.  QRTPCR was also performed as previously 
described (Basso et al., 2009), starting from 2μg total RNA or a percentage of 
RNA from IP fraction.  QPCR analysis of cDNA was performed with ABsolute 
Blue Sybr Green Master Mix (Thermo Scientific) using an AB7300 thermocycler 
(Applied Biosystems). 
 
Western blot and 3ʼUTR reporter assay 
Cell pellets were lysed in RIPA buffer followed by 10 minutes of sonication, 
cleared of debris by centrifugation, and then quantified with Bradford Reagent 
(BioRad).  50μg protein lysate was run on pre-cast Tris-Glycine gradient gels 
(Novex), transferred to Hybond ECL membrane (GE Healthcare), and subjected 
to standard immunoblotting technique.  Antibody information, incubation 
conditions, and quantification procedures are indicated in Supplemental Materials 
and Methods.  For 3ʼUTR reporter assays, firefly and renilla luciferase activities 
were assayed according to standard protocol using the Dual Luciferase Reporter 
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Argonaute immunoprecipitation was performed as previously described (Basso et 
al., 2009) starting from 1X108 exponentially growing RIVA cells or ~5X107 293T 
cells, with anti-pan-Ago antibody (MABE56, Millipore), or control IgG overnight 
with rotation at 4°C.  Protein G magnetic beads (New England Biosciences) were 
added to lysates, and the mixture was incubated for 3 hours with rotation at 4°C.  
HA-tagged proteins were immunoprecipitated by overnight incubation of lysate 
with EZ viewTM HA affinity beads (Sigma).  Beads were washed and resuspended 
in Trizol Reagent (Invitrogen) or lysis buffer for downstream RNA and protein 
analysis, respectively. 
 
Gene expression profiling and data analysis 
Gene expression profiles were generated from total RNA using the HG-
U133Plus2.0 platform (Affymetrix) according to the manufacturerʼs indications.  
Differential expression was determined by t-test using the geWorkbench software 
suite (Floratos et al., 2010), with a significance cut-off of p<0.05. 
 
Generation and sequencing of small RNA libraries 
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GC B cells were isolated from tonsil tissue by magnetic cell sorting as previously 
reported (Klein et al., 2003). Tonsil tissue was collected at the Columbia-
Presbyterian Medical Center following approval by the institutional ethical 
committee.  DLBCL primary biopsies were excess from diagnostic tissue frozen 
at the time of diagnosis. Total RNA was isolated by Trizol Reagent (Invitrogen) 
and the small RNA fraction was enriched by flashPAGETM fractionation (Ambion). 
Small RNA libraries were generated using the SOLiD Small RNA Expression Kit 
(Applied Biosystems) following the manufacturerʼs indications. SOLiD sequencing 
was performed on 4 libraries of purified GC B cells and 25 libraries of DLBCL. 
Following removal of artifacts and rRNA fragments SOLiD sequences were 
subject to a previously developed pipeline to identify candidate miRNAs (6) while 
tRNA-derived fragments were detected by alignment to the UCSC tRNA 
database (Chan and Lowe, 2009). Normalized small RNA counts were obtained 
by correcting for the size of each library. 
 
Supplemental Materials and Methods 
Plasmids and shRNA 
Expression vectors for transient transfection of tRNA were generated by PCR 
amplification of Gly(GCC) chr1.tRNA68 (chr1:161493501-161493953), Gly(GCC) 
chr17.tRNA5 (chr17:8028941-8029251), and a CU1276 predicted genomic 
precursor (chr19:35115779-35116077) followed by insertion into the multiple 
cloning site of pcDNA3 expression vector (Invitrogen).  CU1276 hairpin-
    
76 
expressing vector was generated by restriction digestion of pcDNA3 vector 
containing the human miR-26a-1 locus (chr3:38010684-38011069) with NaeI and 




ACCTGCACTTGGTGCATTGGCCGGGAATCGACGAGGCC-3ʼ were ligated in its 
place.  An inducible CU1276 hairpin-expressing vector was created by restriction 
digest of the pcDNA3-CU1276_hairpin vector and subsequent subcloning into the 
SfiI sites of pRTS1-GLSVP vector (Bornkamm et al., 2005).  Self-ligated pRTS1-
GLSVP vector containing no insert was used as an empty vector control.  RPA1 
co-expression was achieved by excising the GFP coding sequence by SwaI and 
BglII digestion, and cloning of the full length RPA1 coding sequence plus 3ʼUTR 
into its place. shRNA-expressing plasmids pLKO.1-puro-shCtrl, pLKO.1-puro-
shDICER-58, pLKO.1-puro-shDICER-61, and pLKO.1-puro-shDICER-62 were 
purchased from Open Biosystems.  pIRESneo-HA-FLAG-AGO1, -AGO2, -AGO3, 
-AGO4, and -EGFP were obtained from Addgene (Meister et al., 2004).  The 
RPA1, WHSC1L1, and STAG2 3ʼUTR reporter constructs were generated by 
PCR amplification of human genomic DNA, followed by insertion into the multiple 
cloning site of the pmiRGLO vector (Promega).  RPA1 3ʼUTR-MUT reporter was 










RNA samples were reverse-transcribed with the Superscript II First Strand 
Synthesis Kit (Invitrogen) in the presence of 0.2uM RTFS primer (5ʼ-
TGTCAGGCAACCGTATTCACCGTGAGTGGTTGGTGCATTG-3ʼ).  1/10th of the 
cDNA volume was used as a template for PCR amplification in the presence of 
70nM SS primer (5ʼ-
CGTCAGATGTCCGAGTAGAGGGGGAACGGCGTCGATTCCCGGC-3ʼ), and 
70nM each of MPF (5ʼ-TGTCAGGCAACCGTATTCACC-3ʼ) and MPR (5ʼ-
CGTCAGATGTCCGAGTAGAGG-3ʼ) universal primers.  5s rRNA and RNU66 
were detected from cDNA generated by random hexamer reverse transcription, 
according to gene-specific primers (5srRNAF:  5ʼ-GCCCGATCTCGTCTGATCT-
3ʼ, 5srRNAR:  5ʼ-AGCCTACAGCACCCGGTATT-3ʼ, RNU66F:  5ʼ-
GGTGATGGAAATGTGTTAGCC-3ʼ, RNU66R:  5ʼ-
AGGATAGAAAGAACCACCTCA-3ʼ). 
 
Western blot conditions and antibody information 
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All primary antibody dilutions were prepared in PBS with 0.1% Tween20 and 5% 
BSA.  Dilutions and incubation conditions were as follows:  ACTB (A5441; 
Sigma), 1:5000, 1 hour at room temperature; DICER (13D6; Abcam), 1:1000, 
overnight at 4°C; GFP (JL-8; Clontech), 1:5000, 30 minutes at room temperature; 
RPA1 (2267; Cell Signaling), 1:1000, overnight at 4°C; RPA2 (14692; Santa 
Cruz), 1:500, overnight at 4°C.  HRP-conjugated secondary antibodies anti-
mouse IgG HRP (NA931V; GE Healthcare), anti-goat IgG HRP (2020; Santa 
Cruz), and anti-rabbit IgG HRP (1238850; Boehringer Mannheim) were diluted at 
1:10000 in PBS with 0.1% Tween20, 5% milk, and used for 30mins-3hr 
incubations at room temperature.  Blots were visualized with ECL substrate or 
SuperSignal West Dura ECL substrate (Thermo Scientific).  Where applicable, 







Figure 3.1.  CU1276 is a DICER1-dependent tRNA fragment expressed in B 
cells. 
(A) FASTA sequences of the six annotated Gly(GCC) tRNAs with a perfect match 
to CU1276. CU1276 is highlighted in gray, and underlined. 
(B) Cloning frequency of CU1276 from naïve (N), germinal center (GC), and 
memory (M) B cells purified from human tonsil, and from the Burkitt lymphoma 
cell line Ramos (RA).  Data is derived from analysis of previously published small 
RNA libraries (Basso et al., 2009). 
(C) Northern Blot analysis of total RNA from GC B cells, Ramos, and 293T cells 
transiently transfected with empty vector or a vector encoding for the Gly(GCC) 
chr1.tRNA68.  The three primary bands correspond to the 22nt tRNA fragment 
CU1276, the 74nt mature tRNA, and a high molecular weight tRNA primary 
transcript. 
(D) Western Blot and Northern Blot analyses of 293T cells stably expressing 
control shRNA (shCTRL) or a pool of three Dicer-targeting shRNA (shDicer), 
transiently transfected with empty or Gly(GCC) chr1.tRNA68 vector.  Ethidium 
Bromide (EtBr) staining and immunoblotting for ACTB were used as loading 
















































Figure 3.2.  CU1276 is expressed from at least two independent tRNA loci. 
Northern blot of total RNA from purified germinal center (GC) B cells, the Burkitt 
lymphoma cell line Ramos, and 293T cells transiently transfected with empty 
vector, a vector encoding for Gly(GCC) chr17.tRNA5, a vector encoding for a 
predicted genomic precursor for CU1276, or a vector encoding for Gly(GCC) 
chr1.tRNA68.  Both tRNA-encoding vectors were sufficient to express an ~22nt 






Figure 3.3.  CU1276 is bound by all four human Argonaute proteins and 
functions as a miRNA. 
(A) qRT-PCR of CU1276 in pan-Ago and control IP fractions from RIVA cells.  In 
all QRTPCR graphs, values were normalized to 5s rRNA and plotted relative to 
EGFP IP or control IP levels.  Error bars represent the standard deviation of 
triplicate QRTPCR reactions. 
(B) qRT-PCR of CU1276 in immunoprecipitations (IPs) from 293T cells 
transiently expressing equivalent levels of HA-tagged proteins. 
(C) qRT-PCR of miR-16 and CU1276 in IPs from 293T cells expressing HA-
tagged EGFP, or increasing amounts of HA-tagged AGO1. 
(D) Antisense 3ʼUTR reporter activity in response to CU1276, with or without 
exogenous AGO2 expression.  Firefly luciferase values were normalized to a 
Renilla luciferase control, and plotted relative to reporter co-transfected with 
empty vector; error bars represent the standard deviation of two independent 







Figure 3.4.  CU1276 is downregulated in lymphoma cell lines and primary 
biopsies. 
(A) qRT-PCR of CU1276 in germinal center (GC) samples and B cell lymphoma 
lines, including Burkitt lymphoma (BL), activated B cell-like diffuse large B cell 
lymphoma (ABC-DLBCL), and GC-like diffuse large B cell lymphoma (GCB-
DLBCL); QRTPCR levels were normalized to RNU66, and graphed relative to 
GC1.  Error bars represent the standard deviation of triplicate PCR reactions. 
(B) CU1276 counts from deep sequencing of small RNA libraries from purified 
GC (n=4) and primary biopsies of DLBCL (n=25).  The panel of DLBCL includes 




Figure 3.5.  Normal germinal center B cells and B cell lymphoma lines 
express similar levels of Gly(GCC) tRNA. 
Northern blot analysis of total RNA from purified germinal center (GC) B cells, 
and from a panel of GC-derived lymphoma cell lines, including Burkitt lymphoma 
(BL), activated B cell-like diffuse large B Cell Lymphoma (ABC-DLBCL), and GC-
like diffuse large B cell lymphoma (GCB-DLBCL) subtypes.  Membranes were 
blotted with a radioactive probe complementary to the 3ʼ end of mature Gly(GCC) 
tRNA.  Ethidium bromide staining was used as loading control.  The majority of 
cell lines express levels of tRNA similar to those observed in GC B cells, 
suggesting that any deficiency in CU1276 expression is likely due to mechanisms 




Figure 3.6.  Experimental schematic of CU1276 target candidate 
identification, and validation of CU1276 targets. 
(A) 293T cells were transiently transfected with empty vector, chr1.tRNA68, or 
CU1276 hairpin-encoding vectors.  48 hours post-transfection, cells were 
harvested, and their extracted total RNA was used for gene expression profiling 
with Affymetrix HG-U133Plus2.0 arrays.  Genes that were significantly 
downregulated (threshold p<0.05) in tRNA-, and/or in hairpin-expressing cells 
relative to empty vector transfected cells, were considered for further analysis.  
The statistically significant overlap (p<1E-40) between tRNA-downregulated and 
hairpin-downregulated probes confirms that hairpin delivery of CU1276 
recapitulates its physiological activity on at least a subset of transcripts. 
(B) Overlap of genes containing TargetScan-predicted CU1276 binding sites in 
their 3ʼUTR with those significantly downregulated (threshold p<0.05) upon 
expression of CU1276.  Significant enrichment (Hypergeometric test, p=8.6E-8) 
was observed for CU1276 TargetScan-predicted targets among the genes 
downregulated by tRNA and/or hairpin expression. 
(C) WHSC1L1 3ʼUTR reporter activity in response to Gly(GCC) chr1.tRNA68-
delivered or hairpin-delivered CU1276.  The WHSC1L1 3ʼUTR was not sensitive 
to repression by either tRNA-mediated or hairpin-mediated expression of 
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CU1276.  Mutational analysis of the predicted binding site for CU1276 was not 
pursued.  Firefly luciferase values were normalized to a Renilla luciferase control, 
and plotted relative to reporter activity upon co-transfection of empty vector.  
Error bars represent the standard deviation of three independent experiments, 
each performed in duplicate. 
(D) STAG2 3ʼUTR reporter activity in response to Gly(GCC) chr1.tRNA68- or 
hairpin-delivered CU1276.  The STAG2 3ʼUTR is strongly repressed by hairpin-
mediated delivery of CU1276, with high significance (Studentʼs t-test, p=3.8E-7), 
demonstrating that the CU1276 sequence does indeed interact with this 3ʼUTR.  
However, the effect of tRNA expression was ambiguous, showing robust 
repression in some experiments, and no repression in others.  Although this 
repression did eventually reach a minimal threshold of significance (Studentʼs t-
test, p=3.6E-2), the low magnitude of repression suggests that STAG2 may be 
only weakly targeted by tRNA-delivered CU1276 in this cellular context.  Firefly 
luciferase values were normalized to a Renilla luciferase control, and plotted 
relative to reporter activity upon co-transfection of empty vector.  Error bars 
represent the standard deviation of ten independent experiments, each 





Figure 3.7.  CU1276 directly represses RPA1 
(A) RPA1 3ʼUTR reporter activity in response to CU1276 expression.  Firefly 
luciferase values were normalized to a Renilla Luciferase control, and plotted 
relative to reporter co-transfected with empty vector; error bars represent the 
standard deviation of seven independent experiments, each performed in 
duplicate.  The reporter is significantly repressed by either Gly(GCC) 
chr1.tRNA68- (Studentʼs t-test, p=3.9E-5) or hairpin-mediated delivery (Studentʼs 
t-test, p=8.2E-5) of CU1276. 
(B) Western blot analyses of RPA1 and RPA2 from 293T cells (top) transiently 
transfected with empty, Gly(GCC) chr1.tRNA68-expressing-, or CU1276 hairpin-
expressing vector, and from stable lines of the Burkitt Lymphoma cell line P3HR1 
(bottom) engineered to inducibly express GFP (empty) or GFP plus CU1276 
(CU1276).  GFP indicates successful doxycycline induction of vector. ACTB was 
used as loading control. 
(C) Western blot analysis and graphical quantification of RPA1, RPA2, and 
DICER1, with ACTB used as loading control, from normal germinal center (GC) B 
cells and a panel of GC-derived lymphoma cell lines, including Burkitt lymphoma 
(BL), activated B cell-like diffuse large B Cell Lymphoma (ABC-DLBCL), and GC-
like diffuse large B cell lymphoma (GCB-DLBCL).  The GC sample was obtained 
by pooling cells from two independent donors.  All samples are identical to those 





Figure 3.8.  Western Blot quantifications and qRT-PCR of RPA1 upon 
CU1276 expression. 
(A) Western Blot quantification of RPA1 and RPA2 from 293T cells transiently 
transfected with either Gly(GCC) tRNA-expressing (tRNA), or CU1276 hairpin-
expressing (Hairpin) vector; values are normalized to ACTB expression; error 
bars are the standard deviation of four independent experiments. 
(B) qRT-PCR of RPA1 and RPA2 mRNA levels in 293T cells transiently 
transfected with tRNA- or Hairpin-expressing vector; values are normalized to 
GAPDH expression; error bars are the standard deviation of three independent 
experiments.  RPA1 is not significantly repressed at the mRNA level in this 
cellular context. 
(C) Western Blot quantification of RPA1 and RPA2 from stable P3HR1 cells that 
express either GFP alone (Empty) or GFP plus CU1276 hairpin (CU1276) upon 
doxycycline (Dox) treatment; values are normalized to ACTB expression ;error 
bars are the standard deviation of four independent experiments. 
(D) qRT-PCR of RPA1 and RPA2 mRNA levels in stable P3HR1 cells that 
express either GFP alone (Empty) or GFP plus CU1276 hairpin (CU1276) upon 
doxycycline (Dox) treatment; values are normalized to GAPDH expression; error 
bars are the standard deviation of four independent experiments.  RPA1 mRNA 






Figure 3.9.  CU1276 suppresses proliferation in an RPA1-dependent 
manner. 
(A) Growth curves of P3HR1 stable cell lines containing bidirectional, 
doxycycline-inducible vectors expressing GFP alone (blue line), GFP plus the 
CU1276 hairpin (red line), or RPA1 plus the CU1276 hairpin (orange line).  Data 
is compiled from 8 independent experiments, with each genotype represented by 
4 independently derived bulk populations.  Error bars represent the 95% 
confidence intervals of each cell type, calculated according to a normal 
distribution.  CU1276 expression is sufficient to significantly reduce cellular 
proliferation relative to the GFP control at 96, 120, and 144 hours (Studentʼs t-
test, p=0.0018, p=0.0011, and ***p=0.0002, respectively).  Enforced RPA1 
expression significantly rescues this defect at 96, 120, and 144 hours (Studentʼs 
t-test, p=0.0008, p=0.0324, and *p=0.0120, respectively). 
(B) Enlarged detail of growth curves up to the 96-hour time-point.  At 96 hours 
RPA1 rescue restores growth completely to wild-type levels, but at 120 and 144 
hours the RPA1/CU1276 cells show a significantly lower level of growth than the 
GFP control (studentʼs t-test, **p=0.0063), suggesting that additional CU1276 
targets may also contribute to this phenotype.
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Chapter 4:  tRNA fragments are abundantly 
expressed in B cells, and are broadly 
misregulated in diffuse large B cell lymphoma 
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This chapter contains unpublished small RNA sequencing data contributed by 
Katia Basso and Antony Holmes.  Katia Basso performed sample preparation, 
RNA sequencing, and coordinated the analysis, while Antony Holmes performed 
computational analysis of the data, including mapping of RNA reads, and 




In order to expand our understanding of the tRNA-derived miRNAs expressed in 
B cells, and to gain further insights into the role that they might play in the biology 
of B cell development and oncogenesis, we performed deep sequencing of small 
RNAs from purified samples of naïve, germinal center and memory B cells, as 
well as from a panel of chronic lymphocytic leukemia and diffuse large B cell 
lymphoma primary biopsies.  These cell populations are known to express 
distinct miRNA signatures, and our analysis demonstrates that tRNA-derived 
fragments similarly display strong differential expression between normal cell 
populations, and between normal cells and their oncogenic counterparts.  Of 
particular interest is the discovery that the majority of small RNAs misregulated in 
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diffuse large B cell lymphoma are in fact tRNA-derived.  Taken together, our data 
demonstrate that B cells express an abundant and diverse collection of tRNA-
derived fragments, many of which are regulated in a stage-specific, or 
transformation-specific, fashion; moreover, they confirm that at least a subset of 
these sequences are likely to act as miRNA in vivo.  Although the study of tRNA-
derived fragments is only in its beginning stages, it is likely that these small 




Previous sequencing of small RNAs from purified B cells revealed a class of 
abundantly expressed miRNA-like small RNA matching to tRNA sequences 
(Chapter 2).  Subsequent functional characterization confirmed that a 
representative member of this small RNA set, the 22nt CU1276, is indeed 
generated directly from the 3ʼ end of post-transcriptionally modified mature tRNA, 
and that it possesses the functional characteristics of a microRNA, including a 
DICER1-dependent biogenesis, binding to Argonaute proteins, and the ability to 
repress endogenous mRNA targets in a sequence-dependent manner (Chapter 
3).  These studies suggest that through repression of endogenous RPA1, 
CU1276 can influence key cellular processes with strong relevance to both 
normal B cells and B cell lymphomas (Chapter 3). 
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 Although these experiments are an important proof-of-principle that tRNA-
derived fragments are abundant in B cells and can indeed function as miRNAs, 
they are only a starting point for investigation of these intriguing small RNAs.  Our 
initial study was based on the use of Sanger sequencing to discover and profile 
the expression of small RNAs in a limited set of biological samples (Chapter 3 
and Basso et al. 2009).  This technique was sufficient to generate high-quality 
data for sequences expressed in relatively high abundance, but both the depth of 
coverage and the number of biological samples examined were much lower than 
can be easily facilitated using modern sequencing technologies.  Therefore, in 
pursuit of a more detailed understanding of tRF expression patterns, we applied 
deep sequencing approaches to the small RNA of a panel of normal and 
oncogenic B cells. 
 
RESULTS 
Small RNA sequencing from a panel of normal B cells, and primary 
biopsies of chronic lymphocytic leukemia and diffuse large B cell 
lymphoma cases 
Short RNA libraries were generated by cloning RNA fractions of 15–30nt from 4 
samples of human germinal center (GC) B cells, 4 samples of human naïve B 
cells, 1 sample of human memory B cells, 16 samples of purified chronic 
lymphocytic leukemia (CLL), and 25 biopsies of diffuse large B cell lymphoma 
(DLBCL), including 12 cases of the germinal center B cell subtype (GCB-DLBCL) 
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and 13 cases of the activated B cell subtype (ABC-DLBCL).  Approximately 30 
million reads were analyzed from each library, for a total of approximately one 
billion reads across all libraries.  After mapping to the human genome and 
filtering for annotated RNA entities, these reads were found to cluster into 22081 
non-redundant sequences (Figure 4.1a).  This represents an approximately 10-
fold increase in non-redundant complexity relative to our previous sequencing 
efforts (Chapter 2 and Basso et al., 2009). 
 Of these 22081 sequences, 4625 (21%) match to either the mature 
sequence or the precursor sequence of annotated miRNAs (miRBase v.17), 
while an additional 1350 (6%) match to novel candidate mature or precursor 
sequences previously identified by Sanger sequencing (Chapter 2 and Basso et 
al. 2009).  In total, approximately 27% of unique small RNAs detected in these 
libraries can be traced to miRNAs.  In contrast, 16106 non-redundant small RNAs 
(73%) can be matched to mature tRNAs or primary tRNA transcripts (Figure 
4.1a).  These results suggest that tRNA-derived fragments account for a roughly 
3-fold greater proportion of the total small RNA complexity in B cells than do 
miRNA.  However, tRNAs are highly abundant, and subject to rapid turnover; 
they are therefore likely to produce a large pool of low recurrence, random 
degradation products.  Consistent with this notion, when we consider only 
sequences that are detected with at least 50 counts (approximately five orders of 
magnitude less frequently than the most highly expressed small RNA) in at least 
two independent libraries, the total complexity of tRNA-derived sequences drops 
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to only 928 unique small RNAs (Figure 4.1b); many canonical miRNAs are also 
eliminated by these criteria (Figure 4.1b).  Regardless of functional class, the 
extremely low abundance of these eliminated sequences means that they are 
unlikely to have a meaningful regulatory impact, and they were therefore not 
considered in further analyses. 
Interestingly, every isotype of human tRNA is associated with tRFs 
identified by this study to be expressed in normal B cells, although there is an 
approximately 100-fold difference in abundance between the tRNA with the most 
abundantly detected fragments (Arg) and the least abundantly detected 
fragments (His) (Figure 4.2). 
 
TRNA fragment expression signatures can distinguish between stages of 
differentiation in normal B cells, and between normal B cells and 
lymphoma 
Expression signatures of miRNA can be used to distinguish between different 
mature B cell lineages (Basso et al., 2009), as well as between normal B cells 
and lymphoma subtypes (Calin and Croce, 2006).  Accordingly, unsupervised 
clustering of the samples in this study using expression signatures either of 
miRBase mature miRNAs or of novel miRNA candidates (Basso et al., 2009) 
largely succeeds in reconstructing the phenotypic relationships between normal 
subtypes, between normal cells and tumor cells, and between tumor subtypes 
(Figure 4.3a, b). 
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Importantly, the expression signatures of tRNA fragments alone are also 
sufficient to reconstruct these phenotypic relationships (Figure 4.3c).  This result 
demonstrates that, like annotated miRNAs, tRF sequences are specifically and 
dynamically expressed between stages of B cell differentiation, as well as 
between normal B cells and transformed lymphoma cells.  This finding is 
consistent with the possibility that most or all of the observed tRNA-derived 
fragments in this group have a functional role in these cell types. 
 Interestingly, unsupervised clustering using a combination of all three 
classes—522 annotated miRNA, 162 novel candidate miRNA, and 928 tRFs—is 
more robust than clustering with any single class alone (Figure 4.3d).  This 
analysis perfectly recapitulates known biological relationships between the 
samples (Figure 4.3d), and suggests that all three groups are likely to have 
important roles in B cells. 
 
TRNA fragments are among the most misregulated small RNAs in diffuse 
large B cell lymphoma 
The functional relevance of a number of miRNAs to cancer biology has been 
identified by virtue of their differential expression between lymphoma cells and 
their normal counterparts (Eis et al., 2005; He et al., 2005).  In order to extend 
this analysis to novel miRNAs and tRFs, we performed a supervised analysis to 
identify small RNAs aberrantly expressed in DLBCL. 
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 In a supervised comparison of DLBCL versus all other samples (naïve, 
GC, memory, and CLL), 60 small RNAs were identified to have a significantly 
differential expression (Figure 4.3a).  Strikingly, 44 out of 60 (73%) were tRFs.  
This comparison is especially stark in the subset of small RNAs that are 
significantly downregulated in DLBCL; 26 out of 27 (96%) are tRFs, while only 1 
out of 27 (4%) is a canonical miRNA (Figure 4.3a and Table 4.1).  Canonical 
miRNAs account for 15 out of 33 (45%) small RNAs significantly upregulated in 
DLBCL, but a majority of such sequences, 18 out of 33 (55%) are in fact tRFs 
(Figure 4.4a and Table 4.1). 
 
DISCUSSION 
 A closer look at the significantly misregulated small RNA in DLBCL reveals 
several interesting patterns, the most striking of which is the divergent behavior 
of tRF subtype expression within this disease.  We observe that 100% of the 
significantly downregulated tRFs in DLBCL are of the tRF-3 class (Figure 4.4a, 
Table 4.1).  This list of significantly downregulated sequences includes CU1276, 
a tRF-3 with confirmed miRNA-like properties (Chapter 3).  In fact, CU1276 is the 
single most significantly downregulated small RNA sequence in DLBCL, an 
observation that reinforces the potential importance of this particular tRNA-
derived miRNA to lymphoma biology (Figure 4.4a and Table 4.1).  In contrast to 
the set of downregulated small RNAs, 17 out of 18 (94%) of the upregulated tRFs 
in DLBCL are of the tRF-5 class, while 1 out of 18 (6%) is of the tRF-4 class 
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(Figure 4.4a, Table 4.1).  Several of these aberrantly upregulated tRF-5 
sequences are among the most highly expressed small RNAs in DLBCL cells, 
exceeding all but the most abundant canonical miRNAs in total counts (data not 
shown). 
Based on these observations, a picture of tRF misregulation in DLBCL 
emerges in which tRF-3s are subject to broad decreases in expression while tRF-
5s are subject to broad increases of expression accompanying, or perhaps 
contributing to, the oncogenic transformation of DLBCL.  However, the full 
landscape of tRF expression is not simple.  Although nearly all of the most 
downregulated small RNAs in DLBCL are of the tRF-3 class, the majority of tRF-
3s show no significant differences in expression.  Similarly, although tRF-5s 
account for the majority of significantly upregulated sequences in DLBCL, many 
more tRF-5s are not significantly different between the samples examined in this 
study.  Because so little is yet known about the regulation of tRF biogenesis, or of 
their function, we can only speculate about the causes and consequences of this 
phenomenon. 
TRNAs are one of the most primitive biological molecules, and they fulfill a 
critical role in the fundamental biological process of protein translation.  For this 
reason, the generation of tRFs by cleavage of mature tRNAs implies several 
important differences from the biogenesis of any other known class of small RNA 
molecule.  These differences are especially important to consider in an analysis 
of differential tRF expression. 
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Although the steady-state levels of specific tRNAs can modestly vary 
between cell types (Dittmar et al., 2005), every living cell must express every 
tRNA isotype in order to produce a full complement of functional proteins.  This 
rigid requirement largely diminishes the possibility to regulate tRF levels through 
transcriptional mechanisms, as is common for canonical miRNAs.  Instead, 
regulation at the level of processing is a more likely explanation for the strongly 
differential expression observed between the samples examined in this study. 
The DICER1 enzyme has been experimentally shown to be required for 
the biogenesis of a subset of tRFs (Cole et al. 2009, Chapter 3), and by 
extension, may be required for the expression of the majority of tRFs that arise 
from mature tRNA.  However, this role is surprising and a bit mysterious given 
the fact that tRNAs do not meet the biochemically-established criteria for a 
DICER1 substrate (Hammond, 2005).  Furthermore, in the case of canonical 
miRNAs, there are few reported examples of dynamic regulation at the DICER1 
cleavage step, and it is not clear how the paradigms that have been described for 
canonical miRNAs (Pilotte et al., 2011) might apply in the case of tRNAs.  
Experimental results suggest that such differences are not likely to be due to 
expression levels of DICER1 itself, as cell types with equivalent levels of DICER1 
protein can nonetheless produce very different levels of tRFs (Chapter 3).  One 
possible explanation for this differential activity may lie in modifications to the 
tRNAs themselves, such as methylation (Blanco et al., 2011) that might protect 
them from cleavage, or alternatively, potentiate their cleavage. 
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Additional study will be required to determine whether the differential tRF 
signatures of normal and malignant B cells, for example, can be traced back to 
differences in such post-transcriptional modifications.  And although a functional 
mechanism has been demonstrated for at least one representative sequence of 
one tRF class, it remains to be seen whether this mechanism is shared by all or 
perhaps only by some tRFs, and whether there may yet be additional functions 
for these molecules.  The observations in this study are therefore only a starting 
point for further investigation of the possible consequences of these intriguing 
patterns of tRF expression for the biological phenotype of normal B cells, and B 
cell lymphomas. 
 
MATERIALS AND METHODS 
Generation and sequencing of small RNA libraries 
GC and non-GC B cells were isolated from tonsil tissue by magnetic cell sorting 
as previously reported (Klein et al., 2003). Tonsil tissue was collected at the 
Columbia-Presbyterian Medical Center following approval by the institutional 
ethical committee.  DLBCL primary biopsies and CLL were excess from 
diagnostic tissue or peripheral blood cells frozen at the time of diagnosis. Total 
RNA was isolated by Trizol Reagent (Invitrogen) and the small RNA fraction was 
enriched by flashPAGETM fractionation (Ambion). Small RNA libraries were 
generated using the SOLiD Small RNA Expression Kit (Applied Biosystems) 
following the manufacturerʼs indications. SOLiD sequencing was performed on 4 
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libraries of purified GC B cells, 4 libraries of naïve B cells, 1 library of memory B 
cells, 16 libraries of CLL, and 25 libraries of DLBCL. Following removal of 
artifacts and rRNA fragments SOLiD sequences were subject to a previously 
developed pipeline to identify candidate miRNAs (Basso et al., 2009) while tRNA-
derived fragments were detected by alignment to the UCSC tRNA database 
(Chan and Lowe, 2009). Normalized small RNA counts were obtained by 
correcting for the size of each library. 
 
Gene expression profiling and data analysis 
Differential expression was determined by t-test using the geWorkbench software 
suite (Floratos et al., 2010), with a significance cut-off of p<0.05 and a support 















Figure 4.1.  TRFs represent an abundant class of small RNA expressed in 
normal and malignant B cells. 
(A) Schematic of computational matching of 22081 small RNA reads to precursor 
and mature sequences annotated in miRBase, precursor and mature sequences 
of previously identified novel miRNAs, or primary or mature tRNA sequences 
from the UCSC tRNA database. 
(B) Proportion of small RNA reads matching to precursor and mature sequences 
annotated in miRBase, precursor and mature sequences of previously identified 
novel miRNAs, or primary or mature tRNA sequences from the UCSC tRNA 
database both before (left) and after (right) filtering for abundance.  Many 
sequences from each class fail to meet this minimal expression requirement.  
tRNA-related sequences account for a smaller percentage of the filtered small 





Figure 4.2.  Distribution of tRF abundance in normal B cells by tRNA 
isotype. 
Histogram of normalized tRF counts by tRNA amino acid isotype in the combined 
small RNA libraries of 4 germinal Center, 4 naïve, and 1 memory B cell samples.  
























Figure 4.3.  Normal B cells and tumors display distinct profiles based on 
miRNA and tRF expression. 
Unsupervised clustering of 4 germinal center, 4 naïve, 1 memory, 16 chronic 
lymphocytic leukemia (CLL), and 25 diffuse large B cell lymphoma (DLCL) 
samples according to normalized expression of 
(A) annotated miRNAs 
(B) novel predicted miRNAs 
(C) tRNA fragments (tRF) 
or (D) all features combined.  The combination of all three small RNA features 







Figure 4.4.  The majority of small RNAs aberrantly expressed in diffuse 
large B cell lymphoma are tRFs. 
Supervised clustering of 25 diffuse large B cell lymphoma (DLCL) samples 
relative to 4 germinal center, 4 naïve, 1 memory, and 16 chronic lymphocytic 
leukemia samples.  Biological sample type is indicated across the top edge of the 
heat map (color key on right), while the category of differentially expressed small 
RNA is indicated on the left edge (color key on bottom).  Amongst small RNAs 
with significant differential expression in the DLBCL samples (p<0.05, 23/25 

















CU-64076 tRF-3 tRNA-GlyGCC 3.23 7725.4 14726.0 21039.9 3110.5 284.5 
CU-14843 tRF-3 trna-AlaTGC 3.16 4507.7 5376.8 4022.6 6619.7 963.8 
CU-33512 tRF-3 tRNA-ArgTCG 3.12 1767.7 1557.3 1124.7 977.6 150.9 
CU-24539 tRF-3 tRNA-GlyCCC 3.08 6086.7 9563.0 15823.6 3852.1 669.3 
CU-71476 tRF-3 hsa-mir-720 3.08 7407.4 14969.1 11730.5 4081.4 731.0 
CU-35954 tRF-3 trna-AlaCGC 3.07 4557.6 4766.2 3807.3 4849.3 770.6 
CU-53170 tRF-3 tRNA-ThrCGT 3.07 8271.4 8642.6 13963.5 2709.0 366.8 
CU-16437 tRF-3 tRNA-SerTGA 3.03 13955.2 22085.5 16136.7 11517.4 2546.1 
CU-60112 tRF-3 tRNA-SerAGA 2.98 17792.5 35357.8 29752.8 12386.3 2197.1 
CU-21628 tRF-3 trna-LeuAAG 2.98 1384.0 2405.1 1519.5 1815.2 301.5 
CU-16864 tRF-3 trna-AlaCGC 2.96 4096.0 5643.1 3566.9 6316.8 937.1 
CU-71457 tRF-3 trna-LeuAAG 2.95 2313.4 3675.3 2706.3 2855.7 558.7 
CU-72333 tRF-3 trna-LeuTAG 2.94 6528.5 12258.5 6666.7 8198.5 1382.2 
CU-52871 tRF-3 trna-AlaCGC 2.92 1601.0 2270.1 1618.8 2188.9 361.8 
CU-69646 tRF-3 trna-AlaTGC 2.90 2350.9 2813.7 2019.1 3195.1 481.8 
CU-10576 tRF-3 tRNA-CysGCA 2.87 2670.6 3890.2 4684.4 911.5 156.9 
CU-52374 tRF-3 tRNA-CysGCA 2.86 45695.1 62203.3 68882.1 18735.5 3678.3 
CU-19981 tRF-3 trna-LeuAAG 2.85 4533.6 7514.7 5227.9 6612.9 1184.6 
CU-30076 tRF-3 tRNA-LeuCAG 2.82 50291.3 85437.9 62477.8 64304.8 12429.3 
CU-19995 tRF-3 tRNA-AlaAGC 2.80 10623.1 15281.8 17225.9 7391.4 1762.2 
CU-66234 tRF-3 tRNA-SerTGA 2.79 3637.8 5678.1 4898.4 2526.6 652.9 
CU-19453 tRF-3 trna-CysGCA 2.78 3002.9 3591.4 3333.4 1692.6 303.5 
CU-48969 tRF-3 trna-AlaTGC 2.78 7454.8 7600.2 5242.7 9921.5 1499.5 
CU-57487 tRF-3 tRNA-AlaCGC 2.77 153801.2 157075.7 128284.5 169356.1 30372.8 
CU-57803 tRF-3 tRNA-ThrAGT 2.74 10820.4 11973.0 22281.3 2361.2 468.8 
CU-17585 tRF-3 trna-ProTGG 2.62 2539.8 5206.0 7146.0 971.6 214.1 
CU-37571 miRNA hsa-mir-30e 2.40 14060.5 26620.1 21216.0 23388.6 7118.7 
CU-64280 miRNA hsa-mir-126 -5.85 441.9 134.1 322.5 237.2 61997.0 
CU-36943 miRNA hsa-mir-126 -5.62 220.9 65.5 149.2 91.8 20079.1 
CU-49098 miRNA hsa-mir-10b -5.60 16.6 13.2 29.8 6.8 6144.1 
CU-42511 miRNA hsa-mir-143 -5.12 22.4 28.8 71.9 13.4 10819.7 
CU-36151 tRF-5 tRNA-LysCTT -4.51 4653.4 14861.4 33404.1 11314.7 412232.2 
CU-58852 tRF-4 tRNA-LysCTT -4.50 4286.5 13904.1 30801.5 10568.0 383781.1 
CU-52696 tRF-5 tRNA-LysCTT -4.49 12055.7 35973.6 58740.7 24899.4 535016.2 
CU-54037 tRF-5 tRNA-LysCTT -4.40 194.5 825.0 1190.4 513.3 15156.7 
CU-58425 miRNA hsa-mir-199a-1 -4.39 279.3 156.9 3853.4 213.3 33568.6 
CU-15804 miRNA hsa-mir-145 -4.22 345.5 337.3 914.0 144.7 111749.7 
CU-65295 tRF-5 tRNA-GluTTC -4.16 2568.9 1856.9 2316.6 1658.5 39873.6 
CU-59539 miRNA hsa-mir-218-1 -4.12 4.9 8.8 179.5 3.3 2017.4 
CU-21835 tRF-5 tRNA-GluCTC -4.09 16428.1 17207.2 59375.5 15414.9 380160.4 
CU-10397 miRNA hsa-mir-199a-1 -4.00 62.0 93.3 1005.4 158.2 15065.3 
CU-32072 miRNA hsa-mir-130a -3.90 256.0 291.0 532.5 179.7 7973.1 
CU-24436 tRF-5 tRNA-LysCTT -3.63 35.3 154.1 267.2 81.8 1492.9 
CU-28018 miRNA hsa-mir-100 -3.63 138.1 97.4 1805.9 10.3 15485.2 
CU-55547 tRF-5 tRNA-GluCTC -3.63 595.8 461.9 1815.6 530.0 12407.4 
CU-22160 miRNA hsa-mir-125b-1 -3.60 1035.6 205.7 5281.6 33.6 36435.5 
CU-27162 miRNA hsa-mir-99a -3.59 1719.1 97.4 506.0 16.5 12014.6 
CU-56687 tRF-5 tRNA-GlyGCC -3.51 8721.0 19104.4 97519.9 11848.3 269601.2 
CU-48089 tRF-5 tRNA-GluCTC -3.49 96.2 77.4 238.7 128.5 1374.9 
CU-61565 tRF-5 tRNA-ArgCCG -3.43 128.2 225.9 675.5 115.9 7249.1 
CU-32869 tRF-5 tRNA-Undet -3.38 31.9 61.2 201.6 64.0 3317.4 
CU-61314 tRF-5 tRNA-SeCeTCA -3.38 1696.2 1192.6 1135.5 1460.8 8398.6 
CU-14888 tRF-5 tRNA-LysTTT -3.31 17275.0 64178.7 219117.5 53569.9 1311434.7 
CU-34205 tRF-5 tRNA-GlyCCC -3.29 14648.4 24396.2 150613.4 16642.6 511091.7 
CU-48996 tRF-5 tRNA-LysTTT -3.23 55.1 217.1 801.0 185.6 13986.1 
CU-68154 miRNA hsa-mir-125a -3.08 7914.0 374.0 3380.2 303.8 18888.2 
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CU-35803 miRNA hsa-mir-199b -3.06 302.1 180.5 126.1 469.5 6352.5 
CU-69043 tRF-5 tRNA-ValTAC -2.99 742.7 1437.5 2462.4 1077.0 17307.8 
CU-59831 miRNA hsa-mir-424 -2.95 4689.4 15.9 289.0 23.9 2849.5 
CU-24582 tRF-5 tRNA-HisGTG -2.71 239.7 159.7 657.3 206.2 1931.6 
 
Table 4.1.  List of small RNAs significantly aberrantly expressed in diffuse 
large B cell lymphoma 
A positive Z-score indicates significant downregulation in diffuse large B cell 
lymphoma (DLBCL) relative to memory (M), naïve (N), germinal center (GC), or 





Chapter 5:  Summary and perspectives:  
Implications of tRNA-derived microRNAs in B 




A new class of small RNA flies under the radar 
The preceding chapters have presented evidence that B cells contain a diverse 
and abundant collection of small RNA sequences that match to various regions of 
tRNA primary transcripts or to mature, post-transcriptionally modified tRNA (tRF).  
Initial, low-depth sequencing from a small number of B cell samples detected 129 
tRFs (Chapter 2), while deep sequencing from a much larger panel detected at 
least 928 distinct tRFs, with at least some tRNA fragments matching to all tRNA 
isotypes (Chapter 4).  Experimental investigation of a representative tRF 3ʼ 
sequence (tRF-3), designated CU1276, revealed that this molecule is produced 
by direct cleavage of tRNA, and that, like a canonical microRNA (miRNA) it can 
be bound by Argonaute proteins to form functional silencing complexes (Chapter 
3).  This evidence points to the existence of a widespread, idiosyncratic class of 
regulatory molecule about which very little is known. 
Some tRFs are highly expressed, with an abundance rivaling that of 
canonical miRNA.  And although a truly comprehensive analysis has not yet been 
published in the literature, tRFs have previously been independently reported in 
many different types of human cells (Burroughs et al., 2011; Cole et al., 2009; 
Haussecker et al., 2010; Kawaji et al., 2008; Lee et al., 2009) as well as in 
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organisms spanning diverse branches of the metazoan phylogenetic tree 
(Babiarz et al., 2008; Couvillion et al., 2010; Hsieh et al., 2009).  It is therefore 
likely that the majority of small RNA sequencing studies, dating back to some of 
the very earliest genome-wide searches for novel miRNAs (Lagos-Quintana et 
al., 2001) have to some degree detected tRFs.  Why have tRFs not been more 
extensively studied? 
 The answer is probably intimately tied to the nature of their biogenesis; 
these small RNAs are produced from the cleavage of a class of molecule that 
has already been extensively studied.  With very few exceptions, this work has 
been designed to investigate the primary function of tRNAs, which is in facilitating 
protein translation (Phizicky and Hopper, 2010).  Owing to their fundamental role 
in the cellular machinery, tRNAs are extremely abundant molecules, and are 
subject to rapid turnover by endonuclease digestion (Phizicky and Hopper, 2010).  
Therefore, one might expect that any effort to sequence functional small RNA will 
also detect such uninteresting degradation products—a large net cast into the 
sea is likely to pick up plentiful kelp along with fish.  This a priori assumption is 
implicit in many sequencing studies, as demonstrated by strict computational 
filters that eliminate any small RNA that can be traced to a previously annotated 
RNA entity (Landgraf et al., 2007). 
 However, even without hypothesis-driven experimentation, several lines of 
purely observational evidence contradict the notion that tRFs could be the 
products of random tRNA degradation.  Random degradation processes would 
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be expected to produce fragments of widely differing size, mapping to various 
regions of every tRNA expressed in a given cell.  On the contrary, while the 
individual sequences that define a tRF sequence cluster exhibit some degree of 
heterogeneity, they are, for the most part, precisely processed (Chapter 2, 
Chapter 3).  Furthermore, within a given cell type, the tRFs mapping to some 
tRNAs are highly abundant, while those mapping to other tRNAs are virtually 
undetectable (Chapter 2, Chapter 4).  The production of any single tRF can 
dramatically differ between cell types (Chapter 2, Chapter 4), even cell types that 
express equivalent levels of the tRNA from which the tRF is derived (Chapter 3), 
and cells of distinct biological phenotype also express distinct tRF expression 
profiles, as would be expected for a class of molecules subject to active 
regulation (Chapter 4).  Deep sequencing does indeed reveal an enormous 
diversity of low-abundance small RNAs that may correspond to random tRNA 
degradation (Chapter 4), but the size and expression properties of these 
molecules differ dramatically from abundant, precisely processed, and 
differentially expressed tRFs. 
 
CU1276 as a model for tRF function in B cells 
Based on the many interesting clues that emerged from analysis of tRNA-
matching sequences expressed in B cells, we hypothesized that these 
sequences might be the product of an alternative mechanism of miRNA 
biogenesis.  In order to test this hypothesis, we selected one tRF sequence, 
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designated CU1276, as the subject of further study.  The appeal of CU1276 was 
several-fold.  First, it was a member of the tRF-3 class, which was by far the 
most abundant group of tRF sequences in our initial normal B cell libraries 
(Chapter 2).  Second, it was 22nt in length, the most classic size for a DICER1-
dependent miRNA.  Third, it did not overlap in sequence with any other abundant 
tRF3.  Fourth, although it was by no means the most highly expressed tRF 
sequence in our libraries, it was clearly detectable by both Northern Blot and RT-
PCR (Chapter 2), an experimental necessity.  And lastly, CU1276 showed a clear 
pattern of differential expression across the very limited number of B cell libraries 
in our analysis (Chapter 2).  
 Experimental investigation revealed that in biogenesis and more 
importantly, in function, CU1276 shared many characteristics with a canonical 
miRNA (Chapter 3).  We confirmed that CU1276 is indeed the product of 
DICER1-mediated cleavage of mature, post-transcriptionally modified Gly(GCC) 
tRNA, and that upon cleavage, CU1276 is bound by all four human Argonaute 
proteins; once loaded into these key proteins of the miRNA induced silencing 
complexes (miRISC), CU1276 can exert a repressive effect on mRNA targets in a 
sequence-specific, miRNA-like manner (Chapter 3).  Based on these 
characteristics, we can confidently designate CU1276 a “tRNA-derived miRNA”. 
 In the course of validating the miRNA function of CU1276, we successfully 
identified one if its endogenous targets, RPA1 (Chapter 3).  This gene expresses 
a 70kD protein that acts as the large subunit of the single-stranded DNA binding 
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complex RPA; as such, its function is critical for any process in which DNA exists 
in a single-stranded state, including DNA replication and DNA repair (Haring et 
al., 2008).  Expression of CU1276 slows proliferation in a lymphoma cell line, a 
phenotype that can be partially rescued by enforced expression of RPA1 
(Chapter 3).  This effect on the DNA dynamics of growing cells was logically 
consistent with the observation that among all small RNAs, CU1276 is the most 
significantly downregulated in DLBCL as compared to normal cells and a less 
aggressive B cell lymphoma subtype (Chapter 4). 
 The behavior exhibited by CU1276 in our experiments raises several 
prominent questions.  Does the phenotype observed upon expression in a 
lymphoma cell line correspond to a measurable in vivo effect on the dynamics of 
the germinal center (GC), where it is normally expressed?  Through repression of 
RPA1, might CU1276 impact additional processes, such as the efficiency of 
AICDA targeting?  Under physiological circumstances, can CU1276 target 
additional genes, such as the partially validated target STAG2 (Chapter 3), which 
might re-enforce this phenotype?  Is CU1276 the only tRF responsible for this 
regulatory program in B cells, or might other tRFs cooperate to reinforce its 
function?  And does the dramatically reduced expression of CU1276 observed in 
biopsies and cell lines of GC-derived lymphomas directly contribute to their 
oncogenic phenotype, or is it simply a secondary consequence of some other 





Although our investigation of CU1276 is an important proof-of-principle for the 
generation and function of tRFs, critical unanswered questions regarding the 
behavior of other tRFs remain.  Regarding tRF-3s, tRF-4s, and tRF-5s, is the 
DICER1-dependent biogenesis demonstrated for CU1276 a general mechanism?  
Independent studies suggest that it may indeed be (Cole et al., 2009; 
Haussecker et al., 2010), but additional work is required to confirm this on an 
individual tRF basis.  Most importantly, is the miRNA-like function possessed by 
CU1276 a general characteristic of tRFs?  Published work suggests that in at 
least some cases, a large fraction of cellular tRF sequences are not associated 
with Argonaute-containing complexes (Cole et al., 2009).  This result is 
consistent with the possibility that tRFs are less preferred Argonaute substrates 
than are canonical miRNA, as suggested by our functional investigation of 
CU1276 (Chapter 3), but it may also point to additional roles not dependent on 
Argonaute binding. 
In contrast to the tRF-3, tRF-4, and tRF-5 class, tRF-1s likely represent a 
special case, in that they are derived from primary tRNA transcripts in an ELAC1-
dependent manner (Lee et al., 2009), and therefore do not require any 
involvement from DICER1 for their biogenesis.  Furthermore, they are at most 
weakly associated with Argonaute proteins (Chapter 2), and do not seem to act 
by a miRNA-like mechanism (Lee et al., 2009); therefore these sequences should 
probably be treated as relatively distinct entities from tRF-3s, tRF-4s, and tRF-5s, 
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and separate studies will be required to understand the details of their biogenesis 
and function.  Nonetheless, these sequences may have important functions, 
given that independently published work suggests that knock-down of certain 
tRF-1 sequences may lead to cell cycle arrest and complete disruption of cellular 
proliferation (Lee et al., 2009). 
Expression profiling of tRFs in normal and oncogenic B cells suggests a 
coordinated program of tRF-3 expression in the GC, and a converse 
downregulation of tRF-3s in GC-derived lymphomas, with tRF-5 sequences 
upregulated (Chapter 4).  Does downregulation of any single tRF-3 necessarily 
occur in concert with the downregulation of other tRF-3s, or can the biogenesis of 
each be independently regulated?  Does the upregulation of tRF-5 sequences in 
cells with low tRF-3 expression also imply a biogenic link between these two 
different tRF classes?  And if these biogenesis events are indeed linked, do tRF 
molecules have scattershot, divergent effects on cellular phenotype, or might 
they contribute in some cases to a coordinated genetic program?  Finally, is the 
rich landscape of tRF expression observed in B cells unique to this specialized 
lineage or, like miRNAs, do these small RNAs play important roles in many 
biological contexts?  Many important questions remain regarding the biology of 
these unusual molecules. 
 
An ever-expanding small RNA universe 
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In the two decades since the discovery of miRNA, a greater understanding of 
their function has opened new horizons in our comprehension of genetic 
regulatory networks.  Simultaneously, through the use of siRNA/shRNA 
technology, researchers have co-opted the machinery used by endogenous 
miRNA signaling to facilitate investigations of nearly every biological process 
studied.  Perhaps just as importantly, the discovery of this previously 
unrecognized class of genetic regulators acted as an important reminder of a 
recurrent theme in the history of biology:  no matter how well we might think we 
understand the inner workings of a living system, there are always additional 
surprises waiting to be uncovered. 
The experiments described in this work make a small addition to the ever-
expanding world of small RNA by highlighting a largely unstudied class of tRNA-
derived genetic regulators that may rival canonical miRNAs in their diversity and 
abundance.  They also serve as yet another reminder that even well studied 
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